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Efficient intracellular delivery of target macromolecules remains a major obstacle 
in cell engineering, cell labeling, and other biomedical applications. Current standard 
methods of intracellular delivery, such as viral transduction and electroporation, do not 
meet the growing needs in the cell engineering field for cost-effective, scalable, and 
efficient delivery that maintains cell viability. This thesis work has discovered the cell 
biophysical phenomenon of convective intracellular macromolecule delivery using 
mechanically-induced, transient cell volume exchange. Ultrafast microfluidic cell 
compressions (<1 ms) are used to cause brief, deformation-induced cell volume loss 
followed by volume recovery through uptake of extracellular fluid. Macromolecules 
suspended in the surrounding fluid enter the cell on convective fluid currents. Convective 
delivery is shown to bypass endosomal transport and is capable of achieving high 
intracellular delivery for a broad range of molecule types and sizes. Cell volume exchange 
is shown to be dependent on strain rate, magnitude of compression, and cell physical 
properties. The results of this thesis have informed the design and optimization of a high-
throughput microfluidic technology capable of efficiently delivering a wide variety of 
macromolecule payloads to various cell types while maintaining viability and proliferation. 
We harness this cell volume exchange behavior for convective intracellular delivery of 
large macromolecules of interest, including plasmids (>2 MDa) and particles (>30 nm), 
while maintaining high cell viability (>95%). Successful experiments in CRISPR-Cas9 
gene editing and intracellular gene expression analysis demonstrate potential to overcome 
the most prohibitive challenges in intracellular delivery for cell engineering. 
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CHAPTER 1. INTRODUCTION AND BACKGROUND 
1.1 Overview of Cell Deformation Mechanics 
Cells respond to mechanical forces by undergoing deformation behavior that is 
similar to that of a viscoelastic solid. Studies of the deformation of various cell types have 
demonstrated that cell mechanical behavior can be characterized by both elastic and 
viscous behavior, and that cells are able to change and recover shape in response to 
mechanical deformations [1-9].  
1.1.1 Regimes of Cell Deformation Behavior 
Cell deformation behavior has been characterized by micropipette aspiration, 
rheometers, and atomic force microscopy (AFM). These studies have shown that the 
viscoelastic mechanical response of cells to deformations depends on the time scale of 
deformation onset. At slower deformation onset time scales (>0.01 s), cells have been 
observed to have elastic behavior governed by soft-glass rheology dynamics [1-5]. In soft-
glass rheology dynamics, cells undergo gradual deformation that is not dependent on 
deformation time scale [1,3,4]. At faster deformation onset time scales (<0.01 s), cells 
demonstrate viscoelastic behavior in which apparent cell modulus increases with a faster 
deformation time scale. This regime of cell mechanical behavior appears to be governed 
by actin network rheology (Figure 1.1) [2,5,6]. Therefore, the time scale at which cells 
transition from an undeformed state to a fully deformed state affects the biomechanical 
behavior that governs the cell deformation response. With slower deformation, the cell 
 2 
follows soft-glass rheology behavior. During faster deformations, the cell behaves as a 
viscoelastic material.  
 
Figure 1.1: Cell viscoelastic behavior in different deformation regimes. Cells deformed 
at time scales >0.01 s demonstrate soft-glass rheology, or mechanical behavior dominated 
by elastic material properties. Cells deformed at faster time scales <0.01 s exhibit actin 
network rheology, or viscoelastic behavior governed by the properties of the actin network. 
There is potential for a third regime of slow creep to exist at time scales >10 s, but the 
mechanisms that govern this regime are still unknown. Figure reproduced with permission 
from reference [5]. 
Over the duration of compression at a constant strain, cells exhibit creep expansion 
in a direction orthogonal to the compression. This expansion is characterized by an initial 
elastic deformation response followed by a slower viscoelastic creep [7-9]. Studies in 
which cells are fully aspirated into a micropipette were conducted to observe cell 
deformation behavior in these regimes (Figure 1.2A,B). Micropipette studies have shown 
that a cell undergoing compression exhibits an initial phase of elastic, rapid expansion in 
the direction orthogonal to the applied force, followed by a slower viscoelastic creep phase 
until equilibrium is reached (Figure 1.2C) [7,9]. Biophysical studies of slower, gradual 
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deformations show that cells exhibit viscous deformation behavior without changing in 
volume [10-13]. Rapid cell compression by micropipette aspiration can cause cells to lose 
some intracellular volume [7,9]. The magnitude of volume loss is shown to be dependent 
on the ratio of the cell diameter to the micropipette diameter (Figure 1.2D) [7,9]. While the 
time scale at which this cell volume loss occurs is described as being on the same order of 
the aspiration time, the compression time scale required for cell volume loss was not 
precisely quantified. The question of the time scale at which cells transition from the 
regime of  volume conservation to the regime of volume loss during compression is a major 
motivator for this thesis work.  
 
Figure 1.2: Cell deformation and volume change in micropipette study. (A) A human 
chondrocyte before aspiration into a micropipette. (B) The same cell after aspiration into a 
micropipette. Cell volume measurements can be extracted from this image. (C) A deformed 
cell exhibits initial elastic expansion orthogonal to the applied force, followed by slower 
viscoelastic creep before reaching equilibrium. Figures reproduced with permission from 
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reference [7]. (D) Measurement of cell volume change during micropipette aspiration. As 
cell diameter (Dc) gets increasingly larger than micropipette diameter (Dp), the volume 
ratio (J = V/Vo) decreases. Therefore, cells that are much larger than the micropipette 
diameter lose more volume. Figure reproduced with permission from reference [9]. 
 
1.1.2 Cell Recovery after Deformation 
After deformation, cells recover to their pre-deformation shape [12,14,15]. The time 
scale of cell recovery is shown to be dependent on the time scale of duration of the 
deformation. Cells that experience a compression that is short in duration will relax on a 
faster time scale, whereas cells that experience a longer compression will relax slower [15]. 
Following a brief compression, cells exhibit fast cell shape recovery that is consistent with 
rapid, poroelastic recovery behavior of the cytoplasm at short time scales (<0.5 s) after 
brief compression [15,16].  
Cells that lose volume during compression must return to their pre-compression 
volume as they recover shape after deformation. We hypothesize this volume recovery 
would require cell uptake of surrounding fluid volume, including solvent and any 
molecules suspended therein. However, studies of rapid cell mechanical compression have 
not characterized the phenomenon of cell volume recovery after mechanically-induced 
volume loss. The mechanism and nature of this cell volume recovery behavior is another 
major motivation for this thesis work. This cell volume recovery behavior is of interest not 
only to broaden our understanding of cell deformation mechanics, but also as a potential 
mechanism for intracellular delivery of target molecules suspended in the surrounding 
buffer. 
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1.2 Intracellular Delivery Mechanisms 
The efficient delivery of molecules into cells to change or analyze their 
physiological state is an indispensable need for a wide range of biomedical uses, ranging 
from diagnostics to cell therapy manufacturing. The demand for engineered cells is 
increasing rapidly with the emergence of life-saving clinical applications in regenerative 
medicine, gene editing, and cell immunotherapies. However, cell manufacturing is 
drastically hindered by the cost and inefficiency of current techniques for intracellular 
delivery of macromolecules. Cell therapies require cell engineering methods that can 
efficiently process therapeutic doses on the order of 1 billion cells at low cost. The resulting 
cell therapeutic product should also be high in viability, since low viability in therapeutic 
cells can adversely affect treatment outcomes [17-19]. Therefore, the FDA recommends 
that therapeutic cell infusions have viability of at least 85% [20,21]. Furthermore, there are 
several cargo types of interest for intracellular delivery, so an ideal delivery method should 
be capable of delivering molecules with diverse material properties [22]. However, existing 
techniques for intracellular delivery of macromolecule and particle reagents do not 
adequately meet the growing demands in the cell therapy industry for scalability, high cell 
viability, and broad applicability for many cell and molecule types.  
1.2.1 Viral Transduction 
Viral transduction is one of the earliest developed gene editing methods and 
remains one of the most widely used cell engineering techniques in both clinical and 
research settings. However, viral transduction is restricted in clinical applications by high 
costs, scale-up limitations, and long-standing safety concerns associated with random 
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insertional mutagenesis [23-29]. Furthermore, viral capsids have packing limits that restrict 
their applications in the delivery of large genetic constructs. The two most commonly used 
viral vectors, adeno-associated virus and lentivirus, exhibited significantly reduced viral 
titers when packaging vector genomes larger than 5 kb and 9 kb, respectively [30,31]. 
Limitations in genetic cargo size is a major drawback, as the cell therapy industry 
increasingly demands multiple gene edits and larger genetic constructs to prevent disease 
relapse and improve the safety and efficacy of cell therapies  [32,33].   
1.2.2 Endocytic Particles 
Non-viral endocytic mechanisms for delivering cargo into cells include lipid-based 
particles, cationic particles, cell-penetrating peptides, and polymer particles. These 
methods use chemical or particle carriers attached to the target delivery molecule to induce 
cells to endocytose the cargo. Once internalized by the cell, the cargo must escape the 
endosome before degradation occurs in order to perform their intended functions [25,34-
36]. These particles are significantly lower in cost than viral vectors and have been 
increasingly utilized in research laboratory settings. However endocytic particles can cause 
lasting damage to the cell membrane, have a significant tradeoff between delivery 
efficiency and cell viability, and the endosomal delivery mechanism causes the majority of 
delivered molecules to be detained and degraded in lysosomes [25,34-36]. Furthermore, 
the use of chemical transfection agents can impact cell function and requires more rigorous 
study in order to be approved by the United States Food and Drug Administration (FDA) 




Electroporation is a physical method of intracellular delivery that uses electrical 
currents to form pores in the cell membrane coupled with electrophoresis to drive charged 
target molecules through these pores. Electroporation is a rapid cell engineering method 
that is effective for many cell types. However the electrophoretic driving mechanism is 
only ideally suited for charged molecules and can result in inconsistent delivery with low 
cell viability [25,37,38]. Many intracellular delivery cargoes of interest, such as proteins 
and nanoparticles, do not have charge properties that are favorable for electroporation 
delivery. The inconsistent and cytotoxic nature of electroporation makes it difficult to scale 
up to clinical doses of engineered cells with high viability. Furthermore, electroporation 
has been shown to accelerate cell exhaustion, which complicates the expansion step of the 
cell manufacturing process and limits the persistence and effectiveness of the resulting cell 
therapies [39].  
1.2.4 Mechanoporation for diffusive delivery 
Mechanical methods, such as mechanoporation, are a promising approach to deliver 
molecules directly to the cytoplasm with high cell viability. Mechanoporation has been 
shown to be effective in delivering various target molecules into a variety of human cell 
types [40-45]. A microfluidic implementation of these mechanisms results in high 
throughput processing, up to 106 cells/s. Existing microfluidic mechanoporation methods 
impart shear stress on cells to open pores in the cell membrane. Shear stress can be applied 
as fluid shear by rapidly flowing cells through a narrow microchannel that is larger than 
the cell diameter [40]. Ultrasonic pressure waves focused through a narrow microchannel 
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can also be used to permeabilize cell membranes through acoustic shear poration [25,46]. 
Microfluidic devices can exert frictional shear on cells using microchannels that are smaller 
than the cell diameter; gradual constrictions are used to impart shear stress on cells without 
clogging the single-cell channels [41-44,47-51]. After these methods of microfluidic cell 
shear open pores in the cell membrane, intracellular molecule delivery occurs by diffusion 
down a concentration gradient through the resulting cell membrane pores. While diffusion 
is a universal driving force, it is governed by the Stokes-Einstein Law for diffusion in 
solution (Equation 1.1) [52].  
𝑺𝒕𝒐𝒌𝒆𝒔 − 𝑬𝒊𝒏𝒔𝒕𝒆𝒊𝒏 𝒅𝒊𝒇𝒇𝒖𝒔𝒊𝒗𝒊𝒕𝒚 𝑫 =  
𝒌𝑩 𝑻
𝟔 𝝅 𝝁 𝒓
                                                        (1. 1)  
Where D is the diffusion constant, kB is Boltzmann’s constant, T is temperature, μ 
is the dynamic viscosity, and r is the radius of the diffusing particle. For non-spherical, 
linear macromolecules such as DNA and RNA, diffusivity (D) has the following inverse 
relation with polymer length: D ~ L-v, where v ≅ 0.588 and L is the polymer length [53].  
Therefore diffusion is constrained by the inverse relationship between diffusivity and 
molecule size or length. We note existing approaches to microfluidic mechanoporation 
have shown limited efficiency in the delivery of large macromolecules 
[40,42,44,47,49,51]. While mechanoporation has many desirable properties for 
intracellular delivery, the reliance on diffusion as the sole driving mechanism of molecule 
transport into the cell is a major limitation on the applications of this method for delivery 
of large macromolecules that are of therapeutic interest, such as DNA (>1 MDa). This 
limitation has motivated this thesis work to investigate the cell deformation regime of cell 
volume loss and recovery as a potential new driving mechanism for intracellular delivery.  
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1.2.5 Mechanoporation for convective delivery 
Most physical approaches for delivering exogenous materials into single cells are 
based upon the creation of pores and then using electric charge (electrophoresis) and/or 
concentration gradient (passive diffusion) to drive them in. We provide a new driving force 
of convection through the controlled, transient exchange of cell volume. Convection is 
broadly considered to be a type of mass transfer that occurs due to bulk fluid motion. More 
specifically, mass transfer due to convection occurs due to contributions from both 
diffusion, wherein particles travel down a concentration gradient, and advection, wherein 
particles are directionally transported due to bulk fluid flow [54,55].  
This thesis aims to study the intracellular delivery capabilities of a convective 
driving mechanism. Methods that use diffusion alone as an intracellular delivery driving 
mechanism have been shown to be limited in the size of the molecules that can efficiently 
be delivered [40,42,44,47,49,51]. Our objective is to study a mechanical method of causing 
cells to exchange volume and macromolecules with the surrounding fluid. This method 
utilizes the inherent ability of cells to rapidly deform and then recover shape in response to 
mechanical compression [12,14,15]. In regimes of cell compression in which cells lose 
intracellular volume, we hypothesize that cells must uptake surrounding volume in order 
to recover from deformation and return to pre-compression shape and volume [7,9]. The 
intracellular uptake of external fluid volume would necessitate a bulk fluid flow from the 
cell exterior to the cell interior, and any molecules suspended in that fluid would be carried 
into the cell in an advection-dominated intracellular delivery mechanism. We call this 
convective intracellular delivery phenomenon cell VECT, or cell volume exchange for 
convective transfer.  
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In this thesis, we develop and characterize a microfluidic technology that uses 
purely mechanical interactions to cause cell volume exchange for convective intracellular 
delivery of large macromolecules. The microfluidic device uses rectangular ridges within 
a microchannel to exert abrupt compressions on the cell, resulting in a sudden viscoelastic 
response that results in a change in shape and temporary reduction in volume [14,15,56,57]. 
The compacted cell state creates potential for the cell to uptake surrounding molecules as 
it rapidly recuperates lost volume, causing an influx of surrounding volume and molecules 
that is driven by advection and therefore not subject to the molecule size limitations of 
diffusive delivery.  
The results of this thesis have informed the development and optimization of the 
cell VECT device design for useful applications in intracellular delivery. We 
experimentally determined that intracellular delivery can be improved by increasing the 
magnitude and velocity of cell compressions [58,59]. Our findings show that convective 
delivery occurs at a rapid time scale during cell volume exchange inside the device [58]. 
We found that convective delivery can be repeated and maintained for multiple 
compressions to maximize volume exchange and intracellular molecule delivery [58,59]. 
Effective multiplexing of the cell processing microchannels enables high throughput 
processing (up to 106 cells/s). Successful delivery of large macromolecules and plasmids 
(>2 MDa) demonstrate utility for cell engineering techniques that require the delivery of 
large reagents [58,59]. Cells processed using cell VECT maintain high proliferation and 
viability (>95%) [58,59]. This unique combination of features, including high throughput, 
maintained viability, and efficient delivery of large macromolecules, position cell VECT 
for various useful applications for intracellular delivery.  
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1.3 Motivations for Intracellular Delivery 
There exist a wide variety of useful applications for intracellular delivery of various 
macromolecules in both research and clinical settings. Intracellular delivery of several 
types of molecules, including contrast agents and gene expression probes, allow for cell 
labeling, tracking, and analysis of intracellular gene expression. Delivery of cell 
transfection or gene editing reagents allow for temporary or permanent modification of 
gene expression for research and therapeutic applications. In this thesis we will explore 
potential applications for intracellular delivery for cell labeling and analysis and 
modification of cell gene expression.  
1.3.1 Intracellular labeling and analysis 
The growing field of cell engineering requires assays to characterize the cell state 
in order to monitor gene expression and elucidate gene interaction and signaling pathways. 
To fully understand cell behavior, these assays must be able to provide information on both 
external and internal cell activity. The vast majority of cell proteins are expressed in the 
cell interior. However, current gene expression assays that do not compromise cell viability 
are typically limited to analysis of genes expressed on the cell surface. Current standard 
intracellular gene expression assays analyze DNA, RNA, or proteins extracted from a lysed 
cell. Therefore, these methods are unable to provide information on temporal trends in gene 
expression, since the analysis only takes a snapshot of the cell gene expression profile at 
the moment in time when it was lysed. Furthermore, this method does not provide 
information on the intracellular localization of the gene expression [60,61]. Intracellular 
staining and imaging methods do provide information on intracellular localization of gene 
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expression. However, intracellular staining requires cells to be fixed and permeabilized, 
which prevents tracking of gene expression over time [60,61]. Therefore, the field of cell 
engineering would greatly benefit from gene expression assays that can be performed on 
viable cells, allowing for real-time analysis of intracellular gene expression in living cells 
[60,61].  
While characterization of gene expression levels and protein localization is an 
important capability, a complete understanding of intracellular activities and signaling 
pathways requires the ability to analyze intracellular molecular interactions and 
modifications. The field of in-cell nuclear magnetic resonance (NMR) spectroscopy seeks 
to characterize the molecular structure and interactions of biological molecules in their 
native environment, at physiological conditions in the living cell [62,63]. Analysis of 
intracellular protein interactions and modifications facilitates the study of intracellular 
protein signaling mechanisms and pathways. Detection and analysis of a target protein 
using in-cell NMR requires the target signal to be distinguishable from the background 
signal of other intracellular proteins. Therefore, the target protein concentration usually 
must exceed typical physiological levels in order to be detectable [62,63]. Therefore, in-
cell NMR methods for the study of protein structure and modifications requires methods 
for intracellular delivery of the target proteins above physiological levels.  
Intracellular analysis of gene expression and protein interactions are both valuable 
research tools for the field of cell engineering. In a clinical setting, there are also useful 
applications for intracellular delivery that would potentially integrate into and enhance the 
effectiveness of existing cell therapy methodologies. Current methods in stem cell 
transplant therapies for regenerative medicine typically harvest autologous stem cells and 
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transplant them into a disease site in a single surgical procedure [64,65]. This procedure 
does not allow for cells to be labeled before transplantation, which makes tracking cell 
localization and therapeutic progression difficult. Therefore, clinicians have a very limited 
ability to monitor treatment progression and intervene in the case of complications [66-68].   
Current methods for labeling of therapeutic stem cells for in vivo tracking require 
the cells to be processed in a lab environment, often exposing them to transfection agents 
for several hours. This lengthy processing time does not allow for cells to be harvested, 
labeled, and transplanted in a single surgery, which would require the patient to undergo a 
second surgical procedure, which drives up costs and risks for complications and 
infections. Furthermore, the cells are required to leave the operating room to undergo 
chemical processing, which exposes the cells to potential contamination risks [69] and can 
potentially impact stem cell physiology and potency [70-72]. Therefore, a rapid method of 
intracellular labeling would facilitate a single surgical procedure in which cells can be 
harvested, labeled, and transplanted without leaving the operating room.  
1.3.2 Modification of cell gene expression 
Cell engineering has been applied to great effect in the treatment of cancer through 
cell-based immunotherapies. The field of cell-based immunotherapies, or cell therapies, 
utilizes genetically modified immune cells, typically cytotoxic T-cells, to target and 
eliminate cancer cells. A preponderance of successes in clinical trials has led to the FDA 
approval of chimeric antigen receptor (CAR) T-cells for the treatment of multiple 
indications of B cell lymphoma and B cell lymphoblastic leukemia [73-77]. CAR T-cells 
are a promising cancer therapy wherein patient T-cells are transfected to express an 
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artificial antigen receptor on the cell surface that causes them to target cancer cells for 
externally-induced apoptosis. However, current CAR T-cell manufacturing practices must 
overcome many challenges before they are suitable for large-scale, affordable treatments. 
There are long-standing safety concerns with permanent viral genetic modification of T-
cells [37,78]. Additionally, manufacturing requires 10-14 days of ex vivo T-cell expansion 
and viral transfection. This lengthy and costly process has resulted in newly approved CAR 
T therapies from Kite and Novartis costing several hundreds of thousands of dollars for a 
single treatment. Furthermore, the use of multiple edits in manufacturing CAR T-cell 
therapies has been shown to improve treatment efficacy [32,33]. Targeted insertion of the 
CAR gene at the TRAC locus, rather than a random insertion location, has been shown to 
improve tumor rejection in CAR T therapies [79].  
While CAR T-cells have been approved by the FDA, their effectiveness has mainly 
been limited to blood-based cancers. In the field of solid tumor treatment, T-cell receptor 
(TCR) therapies have shown promising results. However, the field of TCR therapies often 
requires multiple gene edits. In addition to introducing an exogenous, modified TCR gene, 
edits to permanently silence the endogenous TCR gene are used to prevent dangerous and 
unpredictable interactions with the exogenous, edited TCR [80]. Therefore, both CAR T-
cells and TCR therapies would greatly benefit from efficient gene editing techniques that 
facilitate multiple gene edits without prohibitively impacting cell viability or 
manufacturing cost. Overall, the next generation of cell-based therapies would greatly 
benefit from nonviral intracellular delivery methods capable delivering large constructs for 
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CHAPTER 2. THESIS OVERVIEW 
2.1 Introduction to Cell VECT 
In this thesis, we will characterize the newly discovered behavior of cell volume 
exchange caused by rapid mechanical compression and recovery and apply this 
phenomenon for convective intracellular macromolecule delivery. Rapid cell deformation 
is caused by flowing cells through a microfluidic channel with ridges with rectangular 
cross-sections that were repeated within a microchannel to precisely exert abrupt and brief 
compressions upon cells. Hydrodynamic forces maintain high cell velocity throughout 
multiple constrictions, while the angled ridges remove dead cells and clusters of cells 
which could cause occlusions [1-3].  
We determined through high-speed microscopy experiments that volume change is 
increased at higher velocity and magnitude of compression, and that cells were partially 
able to recover their volume on the time scale of ~1 ms after each compressive event. 
Characterization of cell integrity, viability, and related gene expression demonstrated no 
detrimental effects, even for volume changes of up to 30%. 
This surprising ability of cells to rapidly exchange fluid with their surroundings in 
response to ultrafast mechanical compressions presents a potent new way to deliver large 
extracellular molecules and particles into cells that solves limitations imposed by simple 
diffusive transport through mechanically-induced pores. We utilized this method of cell 
volume exchange for convective transfer (VECT) to intracellularly deliver molecules and 
particles suspended in surrounding extracellular buffer. The ability of cell VECT to 
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efficiently deliver large molecules contrasts with currently described delivery methods that 
rely on diffusion, which drastically decreases in delivery with larger macromolecules [4-
10]. We demonstrate rapid delivery into multiple cell types of a variety of molecule types 
and sizes, including dextran (4-2000 kDa), plasmids, mRNA, nanoparticles, and even 100 
nm beads. Thus, this new phenomenon of cell volume exchange under ultrafast mechanical 
deformation enables a multitude of highly valuable cell engineering processes. 
In brief, this thesis will begin by experimentally determining the governing 
parameters of cell VECT. Then we will investigate the intracellular delivery capabilities 
and physiological impacts on the cell caused by cell VECT. Finally we will apply this 
intracellular delivery technique to multiple applications of interest in both research and 
clinical settings. The ultimate goal of the proposed thesis is to gain an understanding of the 
mechanisms behind cell VECT, characterize its delivery capabilities and physiological 
effects on cells, and investigate and optimize the microfluidic device design and operating 
conditions for intracellular delivery in a number of clinical and research use cases. Using 
our cell deformation mechanics and intracellular delivery studies, we will explore the 
mechanisms of cell VECT and its effectiveness for useful applications, including 
intracellular analysis and gene engineering. These objectives will be carried out in the 
following aims.  
 
2.2 Aim 1: Governing Parameters of Cell VECT 
We hypothesize that rapid onset and duration of mechanical compressions of cells 
can cause a transient cell volume loss, followed by volume recovery. This phenomenon of 
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cell volume exchange can be utilized for convective transfer of large macromolecules to 
the cell interior. This aim seeks to characterize the mechanisms and governing parameters 
of the cell volume loss and recovery phenomenon during cell VECT. Specifically, we will 
study cell physical properties, including size and viscoelastic properties; device 
characteristics, such as the magnitude and number of compressions; and experiment 
parameters like flow rate and cargo concentration. We aim to determine the effects of these 
parameters on cell volume exchange and intracellular delivery. 
 
2.3 Aim 2: Delivery Capabilities and Cell Physiological Effects 
We hypothesize that the volume exchange phenomenon during cell VECT results in 
intracellular delivery mechanism that is convective and therefore not governed by diffusive 
limitations on transport of large molecules. This purely mechanical intracellular delivery 
method would also be independent of endocytic pathways. This aim seeks to 
experimentally determine the intracellular delivery capabilities and the physiological 
impacts on the cell due to cell VECT. In particular, we will investigate the size and amount 
of target molecules that can be delivered. We will study the intracellular localization of 
delivered molecules, and specifically examine whether delivery is endosomal. We will also 
determine the effects of rapid compressions on cell nuclear envelop integrity, viability, and 




2.4 Aim 3: Applications for Cell Engineering 
We hypothesize that the convective nature of cell VECT delivery enables this method 
to be used to deliver a wide variety of target molecules to virtually any human cell type of 
interest for useful applications in cell engineering and analysis. Therefore, we direct our 
intracellular delivery studies to the specific applications of intracellular gene expression 
analysis, temporary cell transfection, and gene editing. The primary goal of this aim is to 
present proof-of-concept validation to demonstrate the utility of cell VECT for multiple 
applications that are useful in clinical and research settings.  
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CHAPTER 3. GOVERNING PARAMETERS OF CELL VECT 
3.1 Introduction 
Studies of the physical response of cells to deformation using micropipettes, 
microcantilevers, and microfluidic manipulations have shown that cells subjected to 
significant deformations of up to 85% strain applied across a range of timescales from ~10 
μs to >1 s have the ability to recover to their pre-deformation shape [1-10]. Studies of cells 
compressed by micropipette aspiration have reported cell volume loss, but have not 
quantified the time scale at which volume loss occurs or characterized the phenomenon of 
cell volume recovery to return to pre-compression volume [9,10].  
High speed imaging of flow-through microfluidics observe large strain 
deformations and recovery from compressions at time scales <1 ms [1,11,12]. Cells were 
observed to recover to their previous volume and shape as cells relax upon leaving the 
compression. We studied whether this phenomenon can deliver extracellular liquid and 
target molecules into the cell on convective fluid currents. We will investigate the 
conditions and parameters of compressions that cause a transient exchange of fluid and 
macromolecules between the cell interior and its surroundings for intracellular 
macromolecule delivery [13-15]. We find the transition of timescales from slow 
compression to fast compression that leads to the volume change phenomenon, the 
subsequent cell volume recovery behavior, and the dependence on compression parameters 
and cell biomechanical properties. We characterize the biomechanical mechanisms of cell 
volume exchange, specifically investigating the dependence of cell volume exchange on 
compression parameters, cell relaxation, and cell physical properties.  
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3.2 Investigation of Cell VECT Mechanism 
We investigate the governing parameters of transient and significant (up to 30%) cell 
volume change in response to large magnitude deformations with ultrafast timescales (~10 
μs). We attained fast deformations by rapidly flowing cells through microfluidic 
constrictions with an abrupt, stepwise compression profile. To characterize this new 
behavior, we employed high speed video microscopy and quantitative fluorescent marker 
delivery to investigate cell deformation, volume loss, and recovery.  
3.2.1 Microfluidic Cell Deformation Causes Cell Volume Loss 
Cell deformation was caused by flowing cells through a microfluidic channel 
containing a multitude of ridges with rectangular cross-sectional profiles to precisely and 
repeatedly exert abrupt and brief compressions upon the cells. Hydrodynamic forces 
maintained high cell velocity throughout multiple constrictions, while the angled ridges 
cleared dead cells and clusters of cells which could cause occlusions [16-18]. As cells 
encountered the rectangular ridges, abrupt shape change was observed as cells compress 
under the ridges to conform to a gap that is smaller than their relaxed diameter (Figure 
3.1A). Cell compression time is the measurement of the amount of time the cell takes to 
traverse the steep edge of the ridge (<1 μm as determined by optical profilometry) at the 
measured cell velocity (~100 mm/s). During this time, cells were observed to deform 
vertically, perpendicular to the direction of flow, by up to 50% of the cell diameter, for a 
vertical deformation velocity on the order of 1 m/s. In contrast, diffusive mechanoporation 
methods use gradual constrictions that deform cells over the course of approximately 50 
μm (as opposed to the <1 μm steep edge of our rectangular ridges), which results in a 
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vertical deformation velocity at least an order of magnitude slower, or <0.1 m/s vertical 
deformation velocity [19]. The sudden shape change caused by the abrupt deformation 
structure of the rectangular ridge was quantitatively characterized by high speed video 
microscopy and analysis (Figure 3.1B).  
 
Figure 3.1: Overview of microfluidic device and volume exchange. (A) Profilometric 
image of the microfluidic channel layout with diagonal ridges. The arrow indicates cell 
flow direction. (B) Light microscopy image with overhead view of K562 cells flowing 
through the microchannel and passing under ridges. (C) Cross-sectional view of a cell 




The volume reduction of compressed cells indicated that a portion of cytosol was 
expelled from the cell interior through a mechanically compromised cell membrane. Cell 
volume recovery, on the other hand, requires extracellular fluid to enter the cell. Since the 
video analysis does not allow us to evaluate cell volume recovery in between the ridges, 
we characterized the dynamics of volume exchange and fluid transfer through the 
compromised cell membrane using fluorescently labeled dextran (Sigma-Aldrich) as a 
tracker molecule. Dextran of various sizes was added to the cell suspension immediately 
before compression experiments. We hypothesized that cell relaxations after each 
compression will cause the extracellular fluid to enter the cell interior transporting 
suspended fluorescent molecules, and that the molecules will partially remain in the cell 
interior after consecutive compressions and cell recovery, serving as an indicator of volume 
exchange (Figure 3.1C). Shortly after compression, the cell membrane undergoes repair to 
reestablish membrane integrity at a rapid time scale, seconds to minutes, after 
permeabilization [19].  
Using a computational cell deformation model [17] combined with area analysis of 
high speed videos of individual cells in the microfluidic channel, we evaluated the change 
in cell volume at several points in the channel (Figure 3.2A). Measurements were taken of 
K562 myelogenous leukemia cell area before compression, and then when entirely 
constrained under each ridge (Figure 3.2Bi). Before compression, each cell was 
approximated as an ellipsoid, while the cell shape under each ridge was approximated to a 
truncated ellipsoid, as determined by a cell deformation model [17] (Figure 3.2Bii,iii). The 
compressed cell height was equal to the ridge gap, which was independently measured by 
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profilometry. Due to the uncertainty of cell shape and orientation between ridges, the cell 
volume between ridges cannot be deduced from its area measurement.  
 
Figure 3.2: Overview of cell volume change measurement. (A) Overlay of the same 
K562 cell (outlined) at multiple positions passing through the ridges. (B) Image analysis 
of the area of a single cell inside the device. The schematic diagram of a cell at (i) the 
captured top view at each respective position; (ii) three dimensional schematic 
representation of the cell at positions before and during compression under first two ridges 
(iii) approximation of the side view of the cell based on channel height at the corresponding 
positions; overlaid view of the cell at different positions (iv) top view; (v) spherical 
projection of cells with same volume as uncompressed and compressed conditions and (vi) 
side view. 
 
Assuming a known gap and modeled cell shape, we determined the cell volume 
before and during compressions. An overlay of cell area measurements at the various 
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positions shows subtle area change, suggesting that the vertical constraint from the ridge 
mainly accounts for the volume change (Figure 3.2Biv). A view of spherical cells with the 
same volume as the compressed cells visualizes the volume change when projected on the 
pre-compression cell (Figure 3.2Bv). Cells exhibited the most significant volume decrease 
at the first ridge due to the sudden change in shape from ellipsoid to truncated ellipsoid 
(Figure 3.2Bvi).  
Using the described methods to measure cell volume , we were able to determine 
the effects of different compression parameters on cell volume loss. Decreasing the ridge 
gap size of the microfluidic device, that is the space between the ridge and the bottom of 
the microfluidic channel through which the cells must compress, led to a greater volume 
decrease between the pre-compression cell and the cell compressed under the first ridge 
(Figure 3.3A). The cell volume proceeded to slightly decrease with each subsequent 
compression to a plateau volume after approximately 8 ridges (Figure 3.3B). We 
experimentally observed that increased compression strain from smaller ridge gaps resulted 
in higher delivery of fluorescent molecules (Figure 3.3C). The measured delivery to cells 
with smaller ridge gap size (5.6 μm) was confounded at the conditions tested due to cells 
flowing around the ridges rather than passing through the smaller gap underneath the 
ridges. Ridges with gaps larger than the K562 cell diameter (14.5 ± 1.5 μm) did not cause 
volume change, and showed lower delivery of 2000 kDa FITC-dextran macromolecules 
(Figure 3.3C) in a manner consistent with existing studies that used fluid shear 
mechanoporation to induce membrane pores, allowing diffusive delivery of molecules 
[17,20]. Increasing ridge gap size from 16 μm to 20 μm resulted in low amounts of dextran 
delivery, but ridge gaps smaller than the cell diameter significantly increase delivery in a 
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manner that increased with smaller ridge gap sizes. Therefore, a ridge gap smaller than the 
relaxed cell diameter can be identified as a threshold at which delivery behavior changes. 
 
Figure 3.3: Impact of compression strain on volume loss and intracellular delivery. 
(A) Percent of cell volume lost under the first ridge increased with smaller device ridge 
gap, n>250, bars are interquartile range. (B) Normalized volume of cells at different ridge 
positions in the channel, n≥45, bars are standard deviation. (C) Intracellular delivery of 
2000 kDa FITC-dextran (0.3 mg/mL) increased with smaller size of ridge gap through 
which cells pass. K562 cells were used for this study.  
 
3.2.2 Faster Compression Time Scale Causes Greater Volume Loss 
Cells were flowed through the ridged microchannel at varying flow rates to observe 
the effects of compression rate on cell volume change. Flow rate through the microchannel 
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was varied from 3.5 mm/s to 275 mm/s with high speed video recording to observe cell 
responses during mechanical compression. A compression ridge gap of 9 μm, previously 
characterized to cause volume change in K562 myelogenous leukemia cells, was used for 
this study [14]. Using a cell deformation model combined with area analysis of high-speed 
videos of individual cells in the microfluidic channel, we calculated the compressed cell 
volume under the first ridge compared to the volume of the ellipsoid cell before 
compression [17].  
At low flow rates, cells were observed to expand in area perpendicular to 
compression when deformed underneath the ridge (Figure 3.4A,B). At higher flow rates, 
cells did not exhibit area expansion under the ridge (Figure 3.4C,D) yet were substantially 
slowed down by the ridges. As flow rate increases, the cell area expansion decreases, 
eventually approaching no area change compared to the uncompressed cell (Figure 3.4E). 
This cell area expansion results in overall conservation of cell volume at slow flow rates, 
but high flow rates cause cell volume loss (Figure 3.4F). This behavior suggests that, as 
cells undergo more rapid compressions, they are unable to expand under the ridge, resulting 
in increased volume loss. This trend plateaued at the highest flow rates we tested, wherein 
the cells appeared to maintain the same area under the compression compared to before 
compression, indicating a maximized volume change for that compression ridge gap size 
of 9 μm.   
We characterized the effects of compression rate on overall cell volume exchange 
by using 2000 kDa FITC-dextran (Sigma-Aldrich) as a molecular tracer. Flow cytometry 
results from these experiments indicated that intracellular delivery of FITC-dextran 
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increased with faster compression rate (Figure 3.4G). Therefore, increased cell volume loss 
due to faster compression results in greater intracellular delivery.  
 
Figure 3.4: Analysis of cell response to compression time scale. K562 cells in 9 μm 
ridge gap device. (A) Cells at the slowest flow rate, 3.5 mm/s, exhibit visible area 
expansion between P0 (before the first compression) and P1 (under the first compression). 
(B) Area expansion is diminished but still visible at 17 mm/s. (C) As flow moves faster, 
140 mm/s, cell area expansion decreases until (D) at 275 mm/s the area under the ridge 
remains the same compared to before the ridge. (E) Plot of cell area increase percentage 
compared to before the cells enter the ridge as a function of fluid flow rate. N ≈ 150 cells, 
bars represent interquartile range. (F) Plot of cell volume loss percentage under the first 
ridge as a function of fluid flow rate. N ≈ 150 cells, bars represent interquartile range. (G) 
Intracellular delivery of 2000 kDa FITC-dextran increased with compression rate. Cell 
recovery time between ridges is kept constant by scaling inter-ridge spacing with flow rate. 
*P < 0.05, N = 3 experiments, bars represent standard deviation. Devices with 7 ridges 
were used to avoid saturation or maximization of delivery that would otherwise obscure 
the effects of compression rate. No Device controls were exposed to the FITC-dextran 
without being processed by the device.  
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In order to understand the physical basis of the time scales of cell responses, it is 
intriguing to note that the Tc at which the cell is unable to expand transverse to applied 
force is of the same order of magnitude (~2 ms) as the time scale of mechanical signal 
transmission in the viscoelastic cytoskeleton (~1 ms) [21]. It is possible that when the cell 
is compressed  with Tc approaching the time scale of mechanical stimulus transmission in 
the cytoskeleton but slower than that of the cytoplasm, the internal fluid pressure increases 
rapidly. Since the membrane is assumed to be held by the cytoskeleton, which cannot 
respond to deformation, the result of the increased pressure is fluid going through the 
membrane. On the other hand, for lower deformation speeds, both fluid and cytoskeleton 
can respond, and the cell volume is conserved. We therefore hypothesize that rapid 
deformation necessitates that the cell loses some of its volume to accommodate the 
compression time scale.  
3.2.3 Relation Between Volume Loss and Cell Physical Properties 
To better understand the physical mechanisms that govern cell VECT, we 
investigated the effect of cell physical properties, including cell size, elasticity, and 
viscosity, on volume change. At constant compression ridge gap size, we observed that 
larger cells exhibited increased volume loss at every flow rate tested. At slower flow rates 
we observed a broader distribution of cell volume change behavior based on cell diameter 
(Figure 3.5A). At faster flow rates the cell volume change shows a stronger correlation 
with size (Figure 3.5B). These observations suggest that cell volume change is highly 
dependent on cell size at faster flow rates. However, at slower flow rates, other cell physical 
properties, like cell viscosity or elasticity, could dominate.  
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 To test the impact of cell elasticity on volume change, high speed video analysis 
was performed on K562 cells treated using a cytochalasin-D (CD) protocol previously 
characterized to lower the cell Young’s Modulus from 0.40 ± 0.22 kPa to 0.21 ± 0.061 
kPa.[17] However, CD treatment did not exhibit a statistically significant impact on cell 
volume loss at two different flow rates and concentrations of CD (Figure 3.5C,D). 
Similarly, a study of cells treated with 20 μM blebbistatin to reduce Young’s modulus also 
did not show a statistically significant change in cell volume loss at multiple flow rates 
(Figure 3.5E) [22,23]. Therefore we conclude that these changes in cell Young’s modulus 
using CD and blebbistatin did not significantly impact volume loss.  
 
Figure 3.5: Investigation of effects of Young’s Modulus changes on cell volume 
change. K562 cells in 9 μm gap device. (A) At slow flow rate, cell volume change has a 
broad distribution in relation to cell area. N ≈ 150 cells, linear regression R2 = 0.319 (B) 
At fast flow rate, volume change shows strong correlation with cell size. N ≈ 150 cells, 
linear regression R2 = 0.819 (C,D) Treatment of K562 cells with CD to decrease cell 
Young’s modulus did not have a significant impact on cell volume change. N = 50, bars 
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represent SD, P > 0.34. (E) K562 cells were treated with 20 μM blebbistatin to decrease 
cell Young’s modulus. 9 μm gap devices used. Bleb inhibition was observed after the 1 
hour treatment. Blebbistatin treatedment did not have a significant impact on cell volume 
loss at multiple flow rates. N = 25, bars represent SD, P > 0.22. 
 
The cell viscoelastic creep response has been shown to play an important role in 
transducing in-plane stresses to out-of-plane stresses and deformations [9,10,24]. 
Therefore we explored viscosity as a governing factor of cell volume change response by 
comparing HL-60 promyelocytic leukemia cells to K562 cells. HL-60 cells were 
characterized by AFM to have higher viscosity and Young’s modulus than K562 cells 
(Figure 3.6, Table 3.1) [16].  
 
Figure 3.6: AFM measurement of cell mechanical properties. (A) Schematic of AFM 
detection of a laser reflected off a deflected cantilever. The cantilever bends when brought 
in contact with a sample, causing the laser spot on the photodetector to move. Cell 
indentation can be extracted by subtracting the amount of deflection by the position of the 
back of the cantilever. (B) The initial aproach portion of the force curve was fit to the 
Hertzian contact model to calculate cell Young’s modulus. The dwell portion of the force 
curve was fit to an exponential decay curve to extract the viscous rate constant. 
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Table 3.1: Table of AFM measurements of cell mechanical properties. Measurements 
were obtained using the methods outlined in Figure 3.6. Values for K562, K562F and HL-
60 cells were taken from published AFM data [16,17].  
 
Studies have shown that cells increasingly behave as a viscous material at faster 
deformation rates [25,26]. Video analysis of cells deforming under the first microfluidic 
ridge determined that both K562 and HL-60 cells decrease in translational velocity relative 
to the surrounding fluid flow when under the ridge (Figure 3.7A). The K562 and HL-60 
cell experiments were controlled for flow rate and cell size to subject the cells to the same 
magnitude and rate of compression. Yet the two cell types demonstrated different volume 
change behavior. We found that at slow flow rates, more viscous HL-60 cells did not 
expand in area perpendicular to the compression as much as K562 cells, and therefore 
showed higher volume change (Figure 3.7B). As flow rate increases, the volume change of 
the two cell types converge, suggesting cells of comparable size lose similar volume at 
faster flow rates.  
To further test the hypothesis that cell viscoelastic properties govern cell area 
expansion and volume loss during compression, we characterized the deformation response 
of K562 cells crosslinked with formaldehyde. Treatment of K562 cells with 4% 
formaldehyde for 30 mins at room temperature has been shown to significantly increase 
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Young’s modulus and decrease viscosity [16,17]. Therefore, formaldehyde-treated K562 
cells (K562F) exhibit more elastic and less viscous behavior. We observed that K562F cells 
exhibited more area expansion and less volume change than untreated K562 cells at the 
same fluid flow rates (Figure 3.7C). Modifications to viscoelastic properties in K562F cells 
also shift the time scale at which volume change occurs. K562F cells required a faster 
compression time scale than untreated K562s in order to achieve the same volume change 
(Figure 3.7D). For example, in order to reach 50% of maximum cell volume exchange, 
untreated K562 cells must be compressed at compression time Tc  ≈ 0.0035 sec, while 
K562F cells require Tc  ≈ 0.0016 sec, about twice the compression speed. Therefore, K562F 
cells exhibited more elastic behavior, expanding more under the ridge and therefore losing 
less volume than untreated K562s at the same compression rates. 
More viscous cells exhibit slower out-of-plane expansion during both the onset and 
duration of deformation, while elastic cell behavior is characterized by rapid 
expansion.[7,9,10,27-29] These observations suggest that cells with higher viscosity 
exhibit less expansion in the initial elastic phase and slower expansion during the 
viscoelastic creep phase. Studies have shown that cells behave as more viscoelastic 
materials during fast deformation [30-32]. With slower deformation, cells behave as more 
elastic materials [30,32-35]. This results in cells at high flow rates exhibiting more viscous 
behavior with less expansion orthogonal to compression, while cells at slower flow rates 




Figure 3.7: Effects of cell viscosity on cell volume change. 9 μm gap devices used. (A) 
Both K562 and HL-60 cells slow down relative to the surrounding fluid flow when they 
interact with the first ridge. (B) Highly viscous HL-60 cells show more volume loss at slow 
flow rates compared to K562 cells. As flow rate increases the volume change converges. 
**P < 0.0001, *P < 0.005, N ≈ 100 cells, whiskers represent 10-90 percentile, 9 μm gap 
devices used. (C) K562 cells were treated with 4% formaldehyde for 30 mins at room 
temperature to increase cell Young’s modulus and decrease cell viscosity. Formaldehyde-
treated K562 cells (K562F) exhibited a statistically significant decrease in volume loss 
compared to untreated cells at the same fluid flow rates. **P < 0.00001, *P < 0.01. N ≥ 25, 
whiskers represent 10-90 percentile. (D) K562F cells required a faster compression time 
scale than untreated K562s in order for the same volume loss to occur. N ≥ 25, lines 
represent best fit to a sigmoidal function.  
 
We visualize this behavior in an illustration (Figure 3.8A,B) and qualitative plot of 
out-of-plane expansion for a more viscous and less viscous cell, based on a model of the 
cell as a viscoelastic solid consisting of an elastic cortical shell surrounding a viscous fluid 
(Figure 3.8C) [10,29]. Therefore, at faster compression due to high flow rate, cells exhibit 
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more viscous behavior. At slower compression due to low flow rate, cells exhibit elastic 
behavior. A more viscous cell would be expected to exhibit less expansion and therefore 
more volume loss than a less viscous cell.  
 
Figure 3.8: Cell viscoelastic behavior changes with compression rate and impacts 
volume loss. (A) Cells at high flow rate faster onset and duration of deformation, resulting 
in more viscous behavior, reduced expansion, and therefore more volume loss. (B) Cells at 
low flow rate compress slower with longer duration of compression, allowing for elastic 
expansion behavior and volume conservation. (C) Qualitative plot of cell out-of-plane 
expansion behavior during deformation. Cells undergo an initial, fast elastic deformation 
phase followed by a slower, viscoelastic creep phase. More viscous cells exhibit less initial 
elastic expansion and slower viscoelastic creep than less viscous cells. 
 
A dimensionless parameterization of the forces involved in the cell compression 
behavior will allow us to contextualize the interactions between external forces and cell 
mechanical properties that result in cell volume loss. To parameterize inertial force divided 
by viscous force, we calculate a Reynolds number (Re) for the vertical compression of 







. However, a plot of Re did not produce a single trend of 
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correlation between Re and volume change among multiple cell types (Figure 3.9A). A 







 , where ρ = density, V = vertical cell compression velocity, L = cell 
diameter, μ = cell viscosity, E = Young’s modulus, A = cell area, but this dimensionless 
number also did not converge to a single trend for multiple cell types. (Figure 3.9B). 
Therefore, it appears that the volume change behavior of multiple cell types over different 
compression rates is not well explained by considering viscous and elastic forces 
individually.  
 
Figure 3.9: Dimensionless ratios of inertial force to viscous and elastic force. (A) 
Reynold’s number (ratio of inertial force to viscous force) was calculated for multiple cell 
types and compression rates. A plot of Re did not show a consensus trend for volume 
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change for multiple cell types at various flow rates. (B) The ratio of inertial force to elastic 
force was calculated for multiple cell types and compression rates. A plot of FI/FE similarly 
did not exhibit a single trend of correlation with volume change. Variables are defined as 
ρ = density, V = vertical cell compression velocity, L = cell diameter, μ = cell viscosity, E 
= Young’s modulus, A = cell area. N ≥ 25, bars represent standard error.  
 
We next evaluated the observed cell behavior by considering the combined effects 
of cell viscosity, elasticity, and compression rate on the resultant volume change. The 
relation between cell viscosity and elasticity during deformation is parameterized using the 
dimensionless Ericksen number (Er), which determines the relation between viscous and 
elastic forces (Equation 3.1) [36,37].   











                                          (3. 1)  
The cell is modeled as a Maxwell viscoelastic material with dynamic viscosity                              
μ = Tv E, [38-40] where E is the Young’s Modulus and Tv is the viscous time constant as 
measured by AFM (Table 3.1). Viscous force is dependent on cell compression velocity   
(V = ΔL/Tc
 where Tc is the compression time measured by video analysis) and a 
characteristic length (L is the relaxed cell diameter, ΔL = L – compression gap). The elastic 
force is defined by Young’s Modulus and A, cell area.  
At slow flow rates, and therefore low Er values, the cell exhibits elastic deformation 
behavior, expanding in area during initial compression [9,10,30,32-35]. The slow flow rate 
also results in longer duration of compression, so the cell also expands transversely due to 
viscoelastic creep, resulting in volume conservation. Higher flow rates result in larger Er 
values, wherein the cell enters a viscoelastic behavior regime during compression onset 
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that causes decreased initial elastic deformation [30-32]. In addition, the shorter duration 
of compression allows less time for viscoelastic creep expansion during compression, 
resulting in an overall decrease in cell volume [5,9,10]. 
We find that several cell types follow the same sigmoidal trend of volume change 
dependence on Ericksen number, as determined by nonlinear regression performed on data 
points from multiple leukocyte and epithelial cell lines (Figure 3.10). To account for 
differences in cell size and compression gap in these data, we examined a ratio of the 
observed cell volume change and the maximum attainable volume change, where the cell 
does not expand in area during compression.  
 
Figure 3.10: Ericksen number as a dimensionless parameterization of cell volume 
loss. A plot of volume change for multiple cell types shows sigmoidal relation with 
Ericksen number (Er). Cell types include leukocyte cell lines K562, HL-60, and 
formaldehyde-treated K562F, and epithelial cell lines HEY and OVCAR-3. N ≥ 25, bars 
represent standard error. 
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At conditions in which Er >>1, in which cell volume change occurs, we observe 
that the time scale (Tc) at which cells transition from fully uncompressed to fully 
compressed under the first ridge is significantly faster than the cell viscous time constant 
(Tv). At these conditions, the cell must deform very rapidly and does not demonstrate the 
area expansion that was observed at small Er conditions. In the cell behavior regime of 
rapid deformation (Tc << Tv), cells are forced to compress at a time scale too fast for 
cytoplasmic remodeling and mechanical stimulus transmission to occur [21]. 
In order to understand the physical basis of the time scales of cell responses, it is 
intriguing to note that the Tc at which the cell is unable to expand transverse to the applied 
force is of the same order of magnitude (~2 ms) as the time scale of mechanical signal 
transmission in the viscoelastic cytoskeleton (~1 ms) [21]. We hypothesize that when Tc 
approaches the time scale of mechanical stimulus transmission in the cytoskeleton, 
deformation occurs too quickly for the cytoskeleton to expand transverse to the 
compression. The cell membrane is also unable to undergo transverse expansion since it is 
attached to the compressed cytoskeleton. Therefore, the internal fluid pressure increases 
rapidly, and fluid leaves the cell as a result. On the other hand, for lower deformation 
speeds, both fluid and cytoskeleton have sufficient time to undergo transverse expansion, 
and the cell volume is conserved. Our findings suggest that rapid deformation necessitates 
that the cell loses some of its volume to accommodate the compression time scale.  
The convergence plot of cell volume change behavior with relation to Ericksen 
number provides a dimensionless parameterization of cell volume loss in response to 
mechanical forces. The collapse of multiple cell types to a single trend of relation between 
volume change and Er suggests a primacy of both viscosity and elasticity in determining 
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the extent of volume change, which was not seen in other parameterizations. Therefore cell 
deformation behavior is governed by the viscoelastic properties of the cell as a whole, and 
cannot be fully characterized by only considering individual cell components alone. 
Various subcellular components, including the cytoskeleton and cytosol, can however be 
contributing factors to the viscoelastic mechanical response of the cell. When mechanical 
forces cause cells to deform at a time scale that exceeds the limits set by cell viscoelastic 
behavior, the cell undergoes permeabilization.  
3.2.4 Characterizing Volume Recovery through Molecular Delivery 
The volume reduction of compressed cells indicated that a portion of cytosol was 
expelled from the cell interior through a mechanically compromised cell membrane. Cell 
volume recovery, on the other hand, requires extracellular fluid to enter the cell. We 
characterized the dynamics of intracellular uptake of surrounding fluid volume and 
molecules through the compromised cell membrane using fluorescently labeled dextran 
(Sigma-Aldrich) as a tracker molecule. FITC-dextran (2000 kDa MW) was added to the 
cell suspension immediately before compression experiments. We deduced that cell 
relaxations after each compression will cause the extracellular fluid to enter the cell interior 
transporting dispersed fluorescent molecules, and that the molecules will partially remain 
in the cell interior after consecutive compressions serving as an indicator of volume 
exchange.  
Based on the correlation between volume loss and molecule delivery, we 
hypothesized that altering the time that the cell relaxes as it moves between consecutive 
constrictions can affect the volume uptake and, therefore, molecular delivery. The 
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relaxation time between ridges was controlled either by varying the ridge spacing or the 
flow rate. We observed that increased flow rate resulted in decreased delivery, while the 
200 μm spacing between ridges consistently resulted in higher delivery than the 100 μm 
spacing (Figure 3.11A). Therefore, the increased relaxation time between ridges led to 
greater delivery (Figure 3.11B), despite differences in flow speed and ridge spacing. We 
also observed that molecular delivery showed diminishing returns past a certain duration 
of cell relaxation between ridges (~1 ms), suggesting a saturation point of relaxation 
(Figure 3.11B). This result is in contrast with diffusive delivery, which increases with faster 
flow rates [41,42].  
 
Figure 3.11: Characterizing cell volume recovery through molecule delivery. (A) 
Molecule delivery of 2000 kDa FITC-dextran (0.3 mg/mL) decreased with faster flow rate. 
However, 200 μm spacing between ridges consistently demonstrated higher delivery than 
100 μm spacing across several flow rates. (B) Delivery increased with greater cell 
relaxation time between the ridges until a plateau was observed. (C) Molecule delivery was 
greater with increasing number of constrictions. The trend plateaued after 14 ridges. K562 





3.2.5 More Compressions Increases Delivery 
The use of multiple ridges causes repetition of cell volume exchange events. 
Increasing the number of ridges in the microchannel greatly increased molecular delivery 
to the cells. We observed a positive and non-linear correlation between the number of 
ridges and molecule delivery. This trend continued to a plateau, wherein devices with 14 
ridges and 21 ridges demonstrated the same delivery for these experimental conditions 
(Figure 3.12). The overlap in delivered fluorescent molecule intensity at 14 and 21 ridges 
suggests that intracellular delivery has been maximized for these particular experimental 
conditions.  
 
Figure 3.12: Impact of repeated compressions on molecule delivery. Molecule delivery 
of 2000 kDa FITC-dextran (0.3 mg/mL) was greater with increasing number of 
constrictions. The trend eventually plateaus, with 14 and 21 ridges showing the same 
fluorescence intensity profile of delivered fluorescent cargo molecules. K562 cells with 9 
μm gap devices were used. 
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 Based on these results, we hypothesize that each ridge compression event results in 
cell volume exchange, bringing the intracellular concentration of the target molecule closer 
to the extracellular concentration. By subjecting the cells to repeated volume exchange 
events by incorporating more ridges into the microfluidic device, we raise the intracellular 
target molecule concentration. Past a certain number of ridges, we no longer observe 
significant increase in delivery, suggesting that the intracellular concentration cannot be 
raised further based on the extracellular concentration.  
3.2.6 Delivery Occurs During Volume Exchange 
To determine the time scale at which delivery occurs during cell VECT, we designed 
an experiment to analyze the relative amount of delivery that occurs during the brief time 
(<0.1 s) of cell compressions inside the device channel and immediately after leaving the 
device. Delivery inside the channel was determined by flowing K562 cells through the 
channel with the target delivery molecules, 2000 kDa FITC-dextran, and then inhibiting 
delivery after the channel by immediately diluting the outlet sample into a molecule-free 
bath (Figure 3.13A). Delivery after the channel was isolated by flowing cells through the 
channel in the absence of target molecules, then exposing the cells to a molecule-rich bath 
immediately after leaving the channel (Figure 3.13B). Molecules were delivered to over 
80% of cells during their <0.1 s transit through the channel, while only ~33% of cells 
exhibited delivery when provided dextran immediately after transit through the 
compressions, even after incubation in the outlet well for >10 minutes. A threshold set at 
the brightest 10% of the No Device control was used to define the lower bound of 
fluorescence for positive delivery (Figure 3.13C). The high delivery obtained primarily 
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during compressions inside the channel supports that cell VECT delivers large 
macromolecules by fluid exchange during compression and relaxation. 
 
Figure 3.13: Study of intracellular delivery during and after compression. (A) 
Delivery during compression inside the device was isolated by flowing cells through the 
device in the presence of target molecules, then immediately plunging the cells into a 
molecule-free bath. (B) Delivery after compression was isolated by flowing cells through 
the device in the absence of target molecules, then plunging cells into a molecule-rich bath 
immediately after leaving the device. (C) Isolation of delivery inside the channel 
demonstrated that >80% of cells successfully uptake molecules during the brief time inside 
the channel. Only ~33% of cells showed delivery after incubating in a molecule-rich bath 
upon leaving the device, n = 3. K562 cells were delivered with 2000 kDa FITC-dextran 
(0.3 mg/mL) using a 9 μm gap device with 14 ridges. 
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3.3 Summary of Cell VECT Mechanism 
Overall, the process of cell VECT can be summarized beginning with cell volume 
loss during rapid compression, followed by cell uptake of surrounding volume and target 
molecules during recovery, and repetition of compressions for maximum intracellular 
delivery of target molecules.  
3.3.1 Cell Volume Loss During Rapid Compression 
The rapid compressions that cells experience in the cell VECT microfluidic device 
are vital for intracellular delivery. As cells flow rapidly down the microchannel, they 
encounter several ridges with a rectangular profile. In order to pass through the ridge, the 
cell must undergo rapid compression. A sufficiently rapid compression will cause the cell 
to lose some of its intracellular volume. Faster compressions have been shown to increase 
volume loss until a maximum is reached for a cell type with a particular gap size. Smaller 
compression gaps impose greater strain on the cells, which also results in greater volume 
loss. We found that the cell behaves as a viscoelastic material, with increasingly viscous 
behavior as the cell undergoes faster compressions. This viscoelastic behavior allows the 
cell to deform at a certain range of time scales while conserving volume. If the cell 
undergoes a compression that exceeds this range of time scales, the cell loses volume. It 
has been found that increased volume loss facilitates increased intracellular delivery of 




3.3.2 Uptake of Surrounding Volume During Recovery 
The loss of cell volume during compression does not cause intracellular molecule 
delivery in and of itself. Instead, cell volume loss creates the potential for intracellular 
delivery to occur because the elastic nature of the cell causes the cell to recover to its 
normal shape and volume after a deformation. Therefore, convective intracellular molecule 
delivery requires cell volume recovery. A cell that loses more volume must also recover 
more volume, and therefore it will uptake more surrounding molecules. Cells that are 
allowed sufficient time to recover volume between compressions were shown to uptake 
more target molecules than cells that had less time to recover. Overall, cell volume loss 
and recovery are both necessary components of intracellular delivery by cell volume 
exchange.  
3.3.3 Repeat Compressions for Maximum Delivery 
The repetition of these compressions causes multiple cell volume exchange events. 
Each volume exchange event raises the intracellular target molecule concentration to be 
closer to the extracellular concentration. Therefore, the use of multiple ridges in the 
microfluidic devices results in increased intracellular delivery of target molecules. This 
trend continues to a plateau, where increasing the number of ridges no longer significantly 
improves delivery. We determined that molecule delivery occurs at a rapid time scale 
during cell compression inside the device, rather than at longer time scales as the cell 
recovers after passing through the device. This finding is consistent with a rapid, 




3.4.1 Fabrication of Microfluidic Channels  
The microfluidic features of this device were molded onto polydimethylsiloxane 
(PDMS) and plasma bonded to a glass slide. A reusable SU-8 mold was made using 
standard two-step photolithography on a silicon wafer. To fabricate the devices, a 10:1 
ratio of PDMS and crosslinking agent was mixed and poured onto the SU-8 mold to form 
the microfluidic channel features by replica molding. The PDMS was then degassed in a 
vacuum chamber and cured for 1 hr at 80°C. The cooled PDMS was then removed from 
the molds and outlets and inlets were punched using biopsy punches. The PDMS was then 
bonded to clean glass slides using a plasma bonder (PDC-32G Harrick) followed by 1 hr 
in a 80°C oven. After cooling, the channels were passivated using 1% bovine serum 
albumin (BSA) for an overnight incubation at 4°C. For more detailed protocols, please see 
Appendix A.1. 
3.4.2 Microfluidic Experimental Setup  
Cells were resuspended in a cell flow buffer consisting of DPBS (-/-) with 0.1% 
BSA, 0.04% EDTA. Experiments in which video was taken used cell flow buffer with the 
addition of 25% Percoll to maintain cell suspension in buffer without settling. The cells 
were isolated from culture media and resuspended in buffer at ~1-5x106 cells/mL with the 
desired concentration of target molecules. The cell-buffer suspension was infused into the 
microfluidic device at a controlled rate using syringe pumps (PHD 2000, Harvard 
Apparatus). A cell flow rate of ~100 mm/s through the channel was used unless the flow 
rate was the independent variable. For delivery experiments, following collection from the 
 55 
outlets, the cells were washed 2X with 10-fold volume DPBS (-/-) to remove residual 
molecules external to the cells 
3.4.3 Cell Culture 
K562 cells from ATCC were cultured in RPMI-1640 supplemented with 10% fetal 
bovine serum (FBS) and 1% penicillin-streptomycin. HL-60 cells from ATCC were 
cultured in IMDM with 20% FBS and 1% penicillin-streptomycin. HEY cells from MD 
Anderson Cancer Center in Houston, TX were cultured in RPMI-1640 with 10% FBS and 
1% penicillin-streptomycin. OVCAR-3 cells from the National Cancer Institute (NCI) in 
Bethesda, MD were cultured in RPMI-1640 with 20% FBS and 1% penicillin-
streptomycin. Adherent cells were passaged using 0.25% Trypsin-EDTA. The cells were 
incubated at 37°C with 5% CO2. 
3.4.4 High Speed Video Microscopy  
The experiments were carried out on the stage of an inverted bright-field 
microscope (Eclipse Ti, Nikon), with a high-speed camera attachment (Phantom v7.3, 
Vision Research). PDMS microchannel deformation was analyzed using extra-fine 
objective focusing on the beginning of the ridge field, where deformation would be highest. 
Our studies were conducted at flow rates in which deformation of the microchannel and 
ridges was not detectable (<1 μm). The minimum flow rate of 3 μL/min was the slowest 
flow rate at which cells would pass under the ridges. High speed (>1,000 fps) videos were 
taken of cells during processing at various segments of the device. 
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3.4.5 Video Analysis for Cell Volume Change 
To measure the cell volume inside the device, we took measurements of the cell 
area from video data and applied volume assumptions based on a cell deformation model. 
For automated measurements, a custom cell tracking algorithm was used to automatically 
track the trajectory and area of cells in the video, with manual measurements used to verify. 
For each tracked cell, the algorithm identified all video frames where the cell was visible, 
and extracted the position and number of pixels it occupied (area). For each manual 
measurement, we took the ellipse that fit to the pixels of the sharpest gray scale intensity 
gradient to represent the maximum projected cell boundary. We calibrated the length scales 
of each image based on known ridge dimensions, which enabled us to translate the number 
of pixels into an area measurement. For each cell, we measured the area before it entered 
the ridge region of the device to determine its uncompressed volume and the area when 
completely under each ridge to determine the compressed volumes. The volume of the 
unperturbed suspension cell was taken as an ellipsoid where radius was extracted from cell 
area measurement and used to calculate volume. The process of calculating a volume 
measurement from a 2-dimensional image of a compressed cell has potential sources of 
error due to the uncertainty of the 3-dimensional shape of the cell under the ridge. To 
address this uncertainty, we considered two cases for cell shape that represent the upper 
and lower limits of possible cell volume. The smallest possible cell volume corresponds to 
the unperturbed ellipsoid case, where the cell maintains an ellipsoid shape with a diameter 
in the Z-plane (into the image plane) equal to the known ridge compression gap as 
measured by profilometry. The largest possible cell volume corresponds to the cylindrical 
case, where the Z-plane height of the cylindrical cell is equal to the known ridge 
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compression gap. To reconcile these two cell shape cases, we modeled the compressed cell 
as a truncated ellipsoid. To calculate the volume of a truncated ellipsoid cell, we applied 
the ellipsoid procedure to the compressed cell area and cut away equal caps that represent 
the volume of the ellipsoid that intersected with the known constraints of the ridge and 
channel bottom. This was considered the maximum reasonable volume for the compressed 
cell as it approached the cylindrical case for larger cells and collapsed back to the 
unperturbed ellipsoid case for smaller cells.   
3.4.6 Statistical Analysis 
GraphPad Prism and Microsoft Excel were used to perform statistical analysis 
(ANOVA and t-test) and generate plots. The curve for Er vs volume change was obtained 
in Prism by transforming the Er values for all four cell types to log, then performing a 
nonlinear regression to a sigmoidal function as a physiologically relevant model of cell 
volume change behavior during the volume change transition phase of Er values and at the 
maximum and minimum Er values.   
3.4.7 Flow Cytometry 
The BD Accuri C6 Flow Cytometer was used to characterize cell uptake of 
fluorescent target molecules. Samples processed with FITC-dextran were excited with a 
488 nm wavelength laser and emission was detected with a 533/30 filter. Fluorescence 
intensity was normalized with respect to the highest intensity group. A threshold 
fluorescence intensity set to include the brightest 10% of the No device control was used 
to gate for positive delivery, unless otherwise stated.    
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3.4.8 Atomic Force Microscopy 
To characterize the mechanical properties of the ovarian cancer cell lines, we used 
force spectroscopy to obtain force-indentation curves with an MFP-3D atomic force 
microscope (Asylum Research) with an integrated optical microscope (Nikon) on a 
vibration isolation table. Cells were grown on glass FluoroDishes (World Precision 
Instruments). For better global stiffness measurements of the cell, 5.46 μm spherical 
polystyrene particles were attached to tipless silica nitride cantilevers (Bruker Probes) 
using a two-part epoxy and dried for >24 hours. The AFM was calibrated by taking a single 
force curve on a clean FluoroDish. The Sader calibration method was used to obtain 
cantilever spring constants (k is approximately 10-25 pN/nm) based on the thermal 
vibration of the cantilever. Cells were indented at 2 μm/s until a force trigger of 10 nN was 
reached. The z position of the cantilever was held in place for 5 seconds, dwelling towards 
the surface, allowing for viscous relaxation of the cell before the cantilever was retracted. 
See Figure ## for schematic of AFM setup, force curve acquisition, and fit. We used custom 
R code to fit the dwell region of the force curve to an exponential decay function to extract 
the viscous rate constant. To extract the cell Young’s modulus, we used custom R code 
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CHAPTER 4. DELIVERY CAPABILITIES AND CELL 
PHYSIOLOGICAL EFFECTS 
4.1 Introduction 
Studies of microscale cell deformations observed by high speed video microscopy 
have elucidated a new cell behavior in which sufficiently rapid mechanical compression of 
cells can lead to transient cell volume loss and then recovery. Our work has discovered that 
the resulting volume exchange between the cell interior and the surrounding fluid can be 
utilized for efficient, convective delivery of large macromolecules (2000 kDa) to the cell 
interior. However, many fundamental questions remain about this cell behavior, including 
the intracellular macromolecule delivery capabilities the physiological effects experienced 
by the cell. In this section we study the relation between intracellular delivery and molecule 
size, the intracellular molecule concentration achieved, and the localization of delivery. 
We also analyze nuclear envelope integrity and intracellular protein loss after the volume 
exchange process. These results define a highly controlled cell volume exchange 
mechanism for intracellular delivery of large macromolecules that maintains cell viability 
and function for invaluable downstream research and clinical applications. 
Efficient intracellular delivery of target macromolecules remains a major obstacle 
in cell engineering and other biomedical applications. The ability of cells to rapidly 
exchange fluid with their surroundings in response to ultrafast mechanical compressions 
opens a potent new way to deliver large extracellular molecules and particles into cells. We 
utilized this method of cell volume exchange for convective transfer (VECT) to 
 64 
intracellularly deliver molecules and particles suspended in extracellular fluid.  The ability 
to efficiently deliver large molecules contrasts with currently described delivery methods 
that rely on diffusion for transmembrane transfer of molecules, which is inefficient for 
large macromolecules [1-7]. Thus, this new phenomenon of cell volume exchange under 
ultrafast mechanical deformation potentially enables a multitude of highly valuable cell 
engineering processes. 
Studies have shown that compression-mediated cell volume change increases with 
higher cell strain and faster strain rate [8-11]. In this chapter, we aim to characterize the 
delivery capabilities of cell VECT with regard to molecule size and intracellular 
localization of the payload. Furthermore, studying the effects of cell volume loss on cell 
physiology will inform the use of this method in research and clinical intracellular delivery 
applications. While cells that undergo volume change were shown to maintain viability, 
other factors of interest such as nuclear envelope integrity and intracellular protein loss 
have not yet been characterized. This aim seeks to characterize the intracellular molecule 
delivery capabilities and the resultant physiological effects on the cell.  
The cell volume exchange phenomenon is implemented in a microfluidic system 
that uses ridges to briefly impose compressions (Figure 4.1A, B). Cells suspended in buffer 
and flowed through the device rapidly pass through a microchannel in which they undergo 
sudden deformations under the ridges (Figure 4.1C), resulting in an abrupt change in shape. 
This compression is designed to have a rapid onset (on the order of 10-100 μs) and brief 
duration (~1 ms as determined by high-speed video microscopy), resulting in a cell 
behavior regime of fast cell volume loss and recovery [9,11,12]. The volume loss and 
recovery can cause cells to uptake surrounding molecules suspended therein (Figure 4.1D), 
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a phenomenon called cell volume exchange for convective transfer (cell VECT). This cell 
behavior has been used to deliver macromolecules to the interior of various human cell 
types using convection, which is not restrained by molecule size for the range tested (4-
2000 kDa) [9,11]. 
 
Figure 4.1: Microfluidic ridge-based cell compressions cause volume exchange. (A) 
Schematic of device layout. See Appendix A.2 for device design details. (B) Optical 
micrograph of microchannel with chevron ridge geometry. (C) Still-frame image from 
video of K562 cells flowing through the microchannel and ridges under light microscopy. 
(D) Schematic of cell permeabilization and volume loss, subsequent recovery, and repeated 





4.2 Characterizing Intracellular Delivery Capabilities 
4.2.1 Convective Delivery Dependence on Molecule Size 
We aimed to characterize the convective nature of intracellular delivery using cell 
VECT by testing the impact of molecule size on delivery. Since diffusion rate is inversely 
proportional to molecule size, diffusive delivery typically shows lower efficiency for larger 
macromolecules [2-7]. In contrast, cell VECT demonstrated intracellular delivery with 
high efficiency (~90% of cells uptake molecules) regardless of molecule size for the range 
tested (Figure 4.2A). This study used an equal buffer concentration (mass per volume) of 
molecules ranging from 4 kDa, roughly the molecular weight (MW) of a small molecule 
drug, to 2000 kDa, which is roughly the MW of a 3200 bp plasmid. This size-independent 
delivery supported our hypothesis that molecule uptake was achieved predominantly by 
advection, which is the directional transport of extracellular molecules into the cell due to 
bulk fluid flow during cell volume recovery [13,14], rather than molecular diffusion 
through membrane pores. We also demonstrated delivery of FluoSphere 100 nm diameter 
fluorescent polystyrene beads (ThermoFisher) to K562 cells as a demonstration of this 
method’s ability to deliver extremely large particles (Figure 4.2B). 
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Figure 4.2: Molecule size capability of intracellular delivery. (A) Delivery was 
independent of molecule size for the range tested (4-2000 kDa FITC-dextran, 0.3 mg/mL). 
No device control with 2000 kDa FITC-dextran. K562 cells with 10.2 μm gap device. (B) 
Delivery of 100 nm fluorescent particles to K562 cells with 7 μm gap device. Confocal 
microscopy shows fluorescent particles (red) delivered to the cell interior after microfluidic 
device processing. Confocal microscopy Z-stacks of the same cell (bottom row) show that 
fluorescent particles are in the cell interior.   
 
4.2.2 Delivery Saturation and Removal 
We tested the dependence of intracellular delivery on extracellular concentration of 
the target molecule. The intracellular molecular delivery was also found to increase with 
higher extracellular concentration of the target molecule (Figure 4.3A) when qualitatively 
analyzed by flow cytometry of a delivered fluorescent tracer molecule, 2000 kDa FITC-
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dextran. To more precisely quantify intracellular delivery, we delivered ferumoxytol iron 
nanoparticles to adipose-derived stem cells (ADSCs). Inductively coupled plasma (ICP) 
mass spectrometry was used to quantify the iron content per cell. Approximating the 
volume of an ADSC to be on the order of 1 pL, we find that the intracellular concentration 
of target molecule reaches ~10-20% of the extracellular concentration (Figure 4.3B,C) 
[15]. This intracellular concentration is reasonable considering that cells, for the most part, 
consist of large internal structures such as the nucleus, membrane bound organelles, and 
the cytoskeleton, and therefore a significant portion of the intracellular volume is 
inaccessible to foreign molecules.  
 
Figure 4.3: Characterizing intracellular concentration of delivered molecules. (A) 
K562 cells processed with 1-300 μg/mL of 2000 kDa FITC-dextran qualitatively increased 
in intracellular delivery when characterized by cell fluorescence intensity. No device 
control with 1 μg/mL. 10.2 μm gap devices used. (B) Iron nanoparticles delivered to 
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ADSCs were quantified with ICP mass spectrometry to reach intracellular concentration 
~10-20% of the extracellular concentration. ADSCs were processed in a 9.6 μm gap device. 
ICP mass spectrometry done by Daldrup-Link Lab, Stanford.  
 
To further explore the hypothesis that cell VECT causes the target molecule 
concentration in the cytosol to reach equilibrium due to repeated compressions, we 
processed previously dextran-positive cells through the device with dextran-free buffer to 
remove the dextran from within the cells. We first delivered 2000 kDa FITC-dextran to 
K562 cells using VECT, then resuspended these delivered cells in FITC-free buffer and 
processed them in the device again for the Removal group. We found that the Removal 
group has a mean fluorescence intensity that matches the No Device group, indicating that 
this method is highly effective in removing previously delivered molecules (Figure 4.4A). 
These results support our assertion that cell VECT achieved molecule concentration 
equilibrium and can remove unbound molecules from the cell interior, a capability not 
demonstrated with diffusive delivery [16]. Similarly, we also delivered a fluorescently 
labeled nonbinding isotype control antibody to human embryonic kidney (HEK) cells and 
then removed the delivered antibodies by processing the cells again using cell VECT in an 
antibody-free buffer (Figure 4.4B). These data suggest that multiple compartments exist 
within the cell, some of which undergo rapid exchange by cell VECT to reach a saturation 
point of exchange with the extracellular molecule concentration.  
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Figure 4.4: Characterizing equilibration with extracellular concentration by removal 
of delivered molecules. (A) 2000 kDa FITC-dextran  (0.3 mg/mL) delivered to K562 cells 
was removed by processing the cells in the device with a FITC-free buffer, N=2. 7 μm gap 
device with 22 ridges used. Fluorescence intensity was normalized to the highest group. 
(B) A non-binding APC IgG1 isotype control antibody (50 μg/mL) was delivered to HEK 
cells using a 7 μm gap device, and then removed by processing the cells through the device 
again in antibody-free buffer. 
 
4.2.3 Intracellular Localization of Delivered Molecules 
The application of cell VECT can address important limitations of intracellular 
delivery platforms. Endocytic intracellular delivery is often confined to endosomes, which 
detain and eventually degrade the delivered reagent in lysosomes. Therefore, the majority 
of target molecules delivered using endocytic mechanisms are unable reach their desired 
intracellular interaction sites due to an inability to escape the endosome [17-20]. Confocal 
imaging of live cells less than an hour after processing with cell VECT shows that the 
fluorescently labeled delivered molecules have a diffuse localization profile throughout the 
cell interior, rather than a punctate profile that is characteristic of endocytosis (Figure 4.5A) 
[21]. These findings suggest that cell VECT delivery does not rely on endocytosis, and 
instead delivers target molecules unencapsulated, directly to the cytosol. Direct cytosolic 
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delivery is more advantageous for a majority of applications since it allows more direct 
access to various intracellular interaction sites of interest, such as the nucleus, ribosomes, 
cytoskeleton, and organelles.  
 
Figure 4.5: Imaging intracellular localization of delivered molecules. (A) Confocal 
microscopy images of a live K562 cell delivered with 2000 kDa TRITC-dextran (0.5 
mg/mL) with diffuse fluorescence profile throughout the cell interior. 10.2 μm gap device 
used. Scale bar 5 μm. (B) Confocal microscopy showed diffuse delivery of Cy5-labeled 
mRNA throughout the interior of a fixed K562 cell with nucleus staining. 7 μm gap device 
used. No Device control showed no such delivery. Scale bar 5 μm, n = 2.  
 
To demonstrate the capabilities of the use of VECT as a highly efficient delivery 
platform for transfection agents, we successfully delivered Cy5-mRNA (TriLink) into 
K562 cells. The cells were stained with Hoechst nucleus stain to visualize the intracellular 
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localization of the Cy5-mRNA (Figure 4.5B). Using confocal microscopy on live cells less 
than an hour after microfluidics, the mRNA was shown to permeate the cell interior. A No 
Device control of K562 cells exposed to Cy5-mRNA without device processing was 
imaged for comparison. 
To further determine the non-endocytic nature of cell VECT intracellular delivery, 
we stained cells with DiO membrane stain, which stains both the exterior plasma 
membrane and intracellular membranes. Cells were also stained with Hoechst nucleus stain 
and then live cells were imaged using confocal microscopy less than an hour after 
microfluidic processing. The intracellular localization of a delivered fluorescently labeled 
noncoding plasmid did not overlap with the localization of fluorescently dyed intracellular 
membranes (Figure 4.6).  
 
Figure 4.6: Imaging nonendocytic intracellular delivery. K562 cells with nucleus and 
membrane staining were delivered with Cy3-labeled non-coding plasmid using a 9 μm gap 
microfluidic device. Cells were stained with DiO membrane stain, which stains both the 
exterior plasma membrane and intracellular membranes. Cy3-plasmid can be observed 
inside the cytoplasm of live cells outside of the areas occupied by stained intracellular 
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membranes. The imaging suggests that a relatively small volume immediately beneath the 
cell membrane undergoes increased exchange with cell VECT.  
 
 Following microfluidic processing, intracellularly delivered molecules will persist 
in the cell cytoplasm. After several hours, they will eventually be sequestered into 
lysosomes and metabolized by the cell. We studied the localization of iron ferumoxytol 
nanoparticles that were delivered to adipose tissue-derived stem cells (ADSCs). Cells were 
imaged ≥ 24 hrs after delivery using transmission electron microscopy (TEM). The 
delivered nanoparticles were observed to be stored in lysosomes, where they are slowly 
metabolized by the cell (Figure 4.7) [15]. This observation is consistent with published 
studies wherein non-endosomally delivered molecules are internally captured over the 
course of several hours and metabolized in lysosomes by the cell [22].  
 
Figure 4.7: Imaging long-term intracellular localization and metabolism of delivered 
molecules. Adipose tissue-derived stem cells (ADSCs) were imaged with transmission 
electron microscopy (TEM). (A) Control ADSCs without delivery showed no 
nanoparticles present in the cytoplasm. (B) ADSCs delivered with iron ferumoxytol 
nanoparticles (10 mg/mL) show particles sequestered in lysosomes in the cytoplasm. TEM 
occurred ≥ 24 hrs after delivery. 9.6 μm gap device used. TEM done by Daldrup-Link Lab, 
Stanford.  
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4.3 Physiological Effects on the Cells 
4.3.1 Nuclear Envelop Integrity 
We next sought to understand the physiological impact of these rapid mechanical 
compressions on the cells. While it has been shown that the cell cytoplasm has a high 
capacity for deformation and recovery even at high strains, the nucleus – typically one of 
the largest and stiffest organelles – can limit the rate of cell deformation [23,24]. The 
demonstrated exchange in volume and macromolecules between the cell and its outside 
environment suggests that the cell membrane is compromised by fast compressions 
[2,9,11,25], but the integrity of the nuclear envelope has not been characterized. Nuclear 
envelope rupture is important to characterize because it has been associated with genome 
instability, aneuploidy, and DNA damage [23,26]. Severe nuclear disruption can cause 
material to leave the nucleus, leading to chromatin protrusions, nuclear fragmentation, and 
chromothripsis [26,27]. 
We used human embryonic kidney HEK-293 cells transduced with fluorescently 
labeled genes for cyclic GMP-AMP synthase (cGAS-mCherry) and nuclear localization 
signal (NLS-GFP) to indicate nuclear envelope rupture and loss of nuclear contents to the 
cytosol, respectively [23,26,28-30]. The cGAS-mCherry is a cytosolic protein that binds 
DNA at sites of nuclear envelop rupture. We used devices with compression gap of 7 μm 
and 5 μm. These gaps impose cell strains of ~0.4 and ~0.6 respectively, which is a typical 
range of strains used in cell VECT [9]. Electroporation was used as a positive control for 
nuclear envelope disruption. Nuclear envelope disruption is indicated by cGAS-mCherry 
accumulation in and around the nucleus at sites of rupture (Figure 4.8A). Compression of 
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cells using cell VECT resulted in ~10% increase in number of cells with nuclear envelope 
disruption (Figure 4.8B). Varying the compression gap size between 7 μm and 5 μm did 
not appear to impact percentage of nuclear rupture. Cells that were positive for nuclear 
envelope rupture did not exhibit a difference in overall nucleus size (Figure 4.8C).  
 
Figure 4.8: Analysis of nuclear envelop disruption in HEK cells. (A) Confocal 
microscopy shows cGAS-mCherry foci nuclear envelop disruption indicator (white 
arrows) present in a minority of 7 μm gap device-processed HEK cells and a significant 
portion of electroporated cells. Cells in insets are zoomed in 5X. (B) Cell VECT treated 
cells displayed cGAS-mCherry in ~15% of cell nuclei compared to ~6% for No Device 
control. Electroporation used as positive control. *P < 0.05, **P < 0.01, N = 3 (C) There 





Figure 4.9: Analysis of nuclear content loss in HEK cells. (A) Confocal imaging shows 
colocalization of NLS-GFP to the Hoechst-stained nucleus in the majority of No device 
and 7 μm gap device cells, with NLS-GFP outside the nucleus in a small minority of cells 
(white arrows). NLS-GFP can be observed outside the nucleus in electroporated cells. Cells 
in insets are zoomed in 5X. (E) Compressed cells exhibit NLS-GFP outside the nucleus in 
<10% of cells but is not statistically significant compared to No Device control. 
Electroporation used as positive control. *P < 0.01, N = 3. 
 
Nuclear content loss was determined by analyzing colocalization of NLS-GFP with 
a Hoechst nucleus stain (Figure 4.9A). Cells processed with cell VECT displayed a small 
(<5%) increase in NLS-GFP loss to the cytoplasm, but this increase was not statistically 
significant (Figure 4.9B). Therefore, we find that rapid, brief compressions with cell VECT 
causes nuclear envelope disruption in a small minority of cells. However, the disruptions 
do not appear to be significant enough to cause nuclear contents to leave the nuclear 
envelope. Therefore, it appears that the extent or duration of nuclear disruption is not 
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sufficient to cause loss of materials from the nucleus to the cytoplasm. Overall the findings 
indicate that the compression conditions typically used in cell VECT have minimal impact 
on nuclear integrity, which indicates a low risk of associated negative effects such as DNA 
damage. In contrast, electroporation substantially damages the nuclear integrity of cells, 
which may partially account for the low proliferative ability of electroporated cells. 
 
4.3.2 Cell Viability and Proliferation 
Understanding the physiological impact of compression-based cell volume loss not 
only confers a deeper understanding of this phenomenon, but also informs its use in 
research and clinical settings. Studies have shown that mechanically-induced cell 
permeabilization may also result in cell damage, as seen in various cell and tissue injuries 
caused by mechanical trauma [31-36]. This permeabilization can have lasting 
physiological effects, particularly in nerve cells [33,36]. However, numerous human cell 
types, including epithelial cells, chondrocytes, and leukocytes, have demonstrated the 
ability to recover from mechanical compression without significant impact on viability and 
function [2,8-12,37]. 
While cell volume was observed to decrease by up to 30% during compressions, 
cells were quickly restored to their initial size with little impact on cell integrity, viability, 
and related gene expression. After microfluidic processing, cell culture and expansion were 
successfully conducted with no change in cell growth rate. Analysis of still images of >800 
cells immediately after microfluidic processing shows <3% change in mean cell size 
compared to cells without microfluidic processing (Figure 4.10A). Similarly, ethidium 
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homodimer-1 (EthD-1) staining of processed cells showed <3% cell death compared to the 
No Device group (Figure 4.10A). We used RT PCR immediately after microfluidics to 
further quantify that the compressions in the microchannel did not impact the expression 
of apoptotic, cytoskeletal, and other signaling genes (Figure 4.10B). A separate, detailed 
study on cell viability after rapid compressions, including expression of apoptotic genes, 
was consistent with this observation [38]. These results suggested that cells recovered 
normal volume and function after the brief volume loss. 
Characterization of long-term viability in K562 cells up to 5 days after 
microfluidics indicated <5% viability loss compared to No Device and Negative controls 
(Figure 4.10C). Negative controls were maintained in culture, while No Device controls 
were exposed to the same buffer and out-of-culture conditions as Device groups. Note that 
all cell groups, including Negative and No Device controls, showed decreased viability at 
days 4 and 5 of culture without passaging due to culture overgrowth. Additionally, device-
treated cells demonstrated rapid proliferation over 5 days on par with that of No Device 
and Negative control groups, doubling roughly once per day (Figure 4.10D). These results 
were not significantly impacted by decreasing the cell compression gap from 9.5 μm (~0.4 
strain) to 7 μm (~0.6 strain) (Figure 4.10C,D).  
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Figure 4.10: Effects of microfluidic compressions on cell viability and function. (A) 
Measured cell size showed minimal impact by device. Viability stain showed device 
processing caused <5% cell death, N = 2. (B) Expression of genes related to cell viability 
and integrity is unaffected by cell VECT. RNA expression of apoptosis-related and 
cytoskeletal genes is unaffected by the microfluidic cell VECT processing. Expression data 
was normalized with respect to the highest expressing gene, Casp3, set to ~100%, N = 2. 
K562 cells in 9 μm gap device used. (C) Cell viability following compression with two 
different device compression gaps has minimal (<5%) change compared to No Device 
controls up to 5 days after microfluidics. Note all cell groups, including Negative and No 
Device controls, showed decreased viability at days 4 and 5 of culture without passaging 
due to culture overgrowth. N = 3, bars represent SD (D) Cells processed by the device also 
appear to proliferate at a rate consistent with No Device and Negative controls. Cells in all 




4.3.3 Intracellular Protein Loss 
To evaluate whether volume loss during rapid compression led to loss of 
intracellular proteins, we performed a gel electrophoresis analysis and mass spectroscopy 
 80 
analysis of extracellular fluid after microfluidic processing to search for proteins that 
originate from the cell interior. We suspended thrice-washed K562 cells in serum-free flow 
buffer and isolated the cells after microfluidic compressions. The cells were removed with 
centrifugation and the concentrated extracellular proteins were stained with SYPRO Ruby 
protein gel stain (ThermoFisher). Gel imaging revealed that the device groups had very 
similar band intensity compared to the No device control. The overall intensity and number 
of protein bands was much lower in the device and No device groups compared to the Cell 
lysate group (Figure 4.11).   
 
Figure 4.11:  Protein gel analysis of proteins lost during cell VECT. Protein in the 
extracellular buffer from device-processed K562 cells was concentrated and stained. 
Protein gel imaging shows cell samples processed with two different device gap sizes have 
very similar protein band intensity profiles to No device control. Cell lysate control group 
has a much higher protein content. 
 
The concentrated extracellular protein from device processing was also analyzed 
with mass spectrometry to further quantify the type and amount of protein present. The 
mass spectrometry results showed the overall peptide-spectrum matches (PSMs) were low 
in the device and No device groups (Figure 4.12). The composition of proteins in the buffer 
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was unchanged in the 9.5 μm gap device compared to the No device group. The 7 μm gap 
device group appears to be selectively enriched for certain intracellular proteins, 
particularly the cytoskeletal proteins actin and myosin (Table 4.1). Overall the extracellular 
buffer of the No device and device groups showed very low PSMs compared to Cell lysate 
control, indicating low protein content. The No device group had only 1.6% of the total 
PSMs of the Cell lysate control, while the 7 μm and 9.5 μm device had 4.4% and 1.6% 
respectively. The overall conclusion is that the amount of protein lost during this 
compression-based cell volume loss is not significant, as the results with both protein gel 
and mass spectrometry are very similar to the No device control, and much lower than the 
Cell lysate control. This conclusion is supported by the maintained cell viability in culture 
after processing.  
 
Figure 4.12: Mass spectrometry analysis of proteins lost during cell VECT. Mass 
spectrometry of the extracellular buffer showed protein composition of device groups 
similar to No Device, but did identify low levels of intracellular proteins that were 
differentially expressed in the device groups, especially the smaller compression gap (7 




Table 4.1: Identification of intracellular proteins in supernatant. Mass spectrometry 
was used to identify the protein types present in the supernatant of each sample group. 
Relative protein abundance is represented by # PSMs (peptide-spectrum matches). In both 
the No device and device groups, overall protein concentration is low compared to the Cell 
lysate group (<5% of the total PSMs of the Cell lysate group) indicating low protein 
content. The No device group had only 1.6% of the total PSMs of the Cell lysate control, 
while the 7 μm and 9.5 μm device had 4.4% and 1.6% respectively. Protein composition is 
unchanged in the 9.5 μm device group compared to No device. The 7 μm device group 
appears to be selectively enriched for certain intracellular proteins, including actin and 
myosin.  Cell lysate was used as a control group, in which >400 different proteins were 
detected. 
 
To explain the observation of low protein loss, we considered the sponge-like 
behavior of the cytoskeleton, which is believed to play a role in intracellular solute 
retention during transmembrane volume transport [37-41]. Cells have also demonstrated to 
ability to modulate cytosolic ion concentration at a rapid time scale (on the order of 
seconds). Intracellular ion concentration modulation is achieved through ion exchange 
across membranes and release of intracellularly stored ions [42-44]. These ion exchange 
pathways have been shown to correct disturbances to ion homeostasis after membrane 
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permeabilization, an important function in cell recovery following mechanical injury. 
Studies of electroporated cells show that Na+/K+ pumps promote repolarization and 
restoration of intracellular Na+ and K+ concentrations [45-47]. The observation of low 
protein content in the extracellular buffer suggests cells recover from compression with 
minimal lysis or loss of intracellular contents, which is consistent with maintained cell 
viability, function, and proliferation. 
 
4.4 Summary of Delivery Capabilities and Physiological Impact 
This section characterizes both the nature and capabilities of intracellular delivery 
using cell VECT. Delivery is shown to be convective, and therefore not subject to the 
limitations in delivery cargo size that have been demonstrated in diffusive delivery [2-7,9]. 
Delivery using cell VECT is shown to raise intracellular target molecule concentration to 
~10–20% of extracellular concentration. Therefore, while convective delivery is shown to 
be independent of molecule size, it is still limited by the extracellular concentration of the 
target reagent. The non-endosomal nature of cell VECT delivery allows intracellular 
cargoes to directly access intracellular interaction sites without being detained and 
degraded in endosomes [17-20].  
Cells also appear to maintain physiological health and function following 
microfluidic compressions. Nuclear envelop disruption is often associated with DNA 
damage and genome instability [23,26]. Device-processed cells were shown to maintain 
nuclear envelop integrity, which would limit access of delivered molecules to the nucleus. 
It is possible that smaller compression gaps (<20% of average cell diameter) could result 
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in increased nuclear envelop disruption, at the additional cost of cell viability. Loss of 
intracellular proteins during compression was found to be similar to No device controls 
and significantly lower than Cell lysate controls. The protein loss studies suggest that there 
is also minimal loss of other intracellular contents, such as mRNA or organelles, although 
these studies would need to be performed in order to validate that claim. Overall, these 
findings are consistent with our observations of minimal impact on cell viability, function, 
and proliferation [9,11]. These findings help validate future potential applications for cell 
VECT in both research and clinical settings.  
 
4.5 Methods 
4.5.1 Fabrication of Microfluidic Channels  
The microfluidic features of this device were molded onto polydimethylsiloxane 
(PDMS) and plasma bonded to a glass slide. A reusable SU-8 mold was made using 
standard two-step photolithography on a silicon wafer. To fabricate the devices, a 10:1 
ratio of PDMS and crosslinking agent was mixed and poured onto the SU-8 mold to form 
the microfluidic channel features by replica molding. The PDMS was then degassed in a 
vacuum chamber and cured for 1 hr at 80°C. The cooled PDMS was then removed from 
the molds and outlets and inlets were punched using biopsy punches. The PDMS was then 
bonded to clean glass slides using a plasma bonder (PDC-32G Harrick) followed by 1 hr 
in a 80°C oven. After cooling, the channels were passivated using 1% bovine serum 
albumin (BSA) for an overnight incubation at 4°C. For more detailed protocols, please see 
Appendix A.1. 
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4.5.2 Microfluidic Experimental Setup  
Cells were resuspended in a cell flow buffer consisting of DPBS (-/-) with 0.1% 
BSA, 0.04% EDTA. Experiments in which video was taken used cell flow buffer with the 
addition of 25% Percoll to maintain cell suspension in buffer without settling. The cells 
were isolated from culture media and resuspended in buffer at ~1-5x106 cells/mL with the 
desired concentration of target molecules. Multiple sizes of FITC-dextran were purchased 
from the same maker (Sigma-Aldrich) with very little variation in labeling fraction. The 
dextran molecules had an average FITC/dextran molar ratio of 0.00525 ± 0.0017. Our 
largest molecule, 2000 kDa, had a labeling fraction of 0.006, almost identical with the 
smallest molecule, 3-5 kDa, labeling fraction of 0.007. We also used the same mass per 
volume, so the mass of fluorophore in solution is the same across all molecule sizes. The 
cell-buffer suspension was infused into the microfluidic device at a controlled rate using 
syringe pumps (PHD 2000, Harvard Apparatus). A cell flow rate of ~100 mm/s through 
the channel was used unless the flow rate was the independent variable. For delivery 
experiments, following collection from the outlets, the cells were washed 2X with DPBS 
(-/-) to remove residual molecules external to the cells. For experiments in which cells were 
cultured following microfluidics, the microfluidic experiment was conducted inside a 
sterile biosafety cabinet. All cell-handling supplies, including the device, syringe, and 
needles, were sterilized by autoclaving.  
4.5.3 Cell Culture 
K562 cells from ATCC were cultured in RPMI-1640 supplemented with 10% fetal 
bovine serum (FBS) and 1% penicillin-streptomycin. HEK-293 cells, a generous gift from 
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Lammerding lab, were cultured in EMEM with 10% FBS and 1% penicillin-streptomycin 
and passaged using 0.25% Trypsin-EDTA. Adipose tissue-derived stem cells were 
harvested from knee joints of Goettingen minipigs. <1mm3 tissue samples from the 
infrapatellar fat pad were collected, placed in type I collagenase (1.5mg/mL, Sigma 
Aldrich) for dissociation, centrifuged and then cultured in adipose-derived stem cell 
specific media. The cultured cells were characterized with specific surface markers for 
ADSCs according to the International Society for Cell Therapy (ISCT) criteria, including 
CD29, CD44, CD71, CD90, CD105/SH2, SH3 and STRO-1 with lack of CD31, CD45 and 
CD106. The cells were incubated at 37°C with 5% CO2. 
4.5.4 Flow Cytometry 
The BD Accuri C6 Flow Cytometer was used to characterize cell uptake of fluorescent 
target molecules. Samples processed with FITC-dextran were excited with a 488 nm 
wavelength laser and emission was detected with a 533/30 filter. Fluorescence intensity 
was normalized with respect to the highest intensity group. The viability of the cells 
immediately after microfluidics was tested by staining with 2 µM EthD-1 (Molecular 
Probes Inc.) solution per manufacturer protocol [48,49] (640 nm excitation and 670 LP 
filter). The long term viability of the cells was tested by propidium iodide staining per 
manufacturer protocol and excited with a 488 nm wavelength laser and emission was 
detected with a 670 LP filter.  
4.5.5 Plasmids and Generation of Fluorescently Labeled Cell Lines 
HEK-293-TN (System Biosciences, SBI) cells were stably modified with lentiviral 
vectors to express the nuclear rupture reporter NLS-GFP (pCDH-CMV-NLS-copGFP-
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EF1-blastiS) and/or cGAS-mCherry (pCDH-CMV-cGASE225A/D227A-mCherry2-EF1-Puro) 
[23]. cGAS is a cytosolic DNA binding protein; we used a cGAS mutant (E225A/D227A) 
with abolished enzyme activity and interferon production, but that still binds DNA and 
serve as a nuclear envelope rupture reporter [50]. To generate stable lines, pseudoviral 
particles were produced as described previously [23]. In brief, HEK-293-TN cells (System 
Biosciences, SBI) were co-transfected with the lentiviral plasmid, packaging and envelope 
plasmids using PureFection (SBI), following manufacturer protocol. Lentivirus-containing 
supernatants were collected at 48 hours and 72 hours after transfection and filtered through 
a 0.45 µm filter. Cells were seeded into 6-well plates so that they reached 50-60% 
confluency on the day of infection and transduced with the viral supernatant in the presence 
of 8 g/mL polybrene (hexadimethrine bromide). After 24 hours, the viral solution was 
replaced with fresh culture medium, and cells were cultured for 72 hours before selection 
with 1 μg/mL of puromycin or 2 μg/mL blasticidin S for 2-5 days. After selection, cells 
were subcultured and maintained in their recommended medium without the continued use 
of selection agents. 
4.5.6 Electroporation 
Electroporation of HEK-293 cells was carried out using an Amaxa Nucleofector II 
and Amaxa Cell Line Nucleofector Kit V using manufacturer protocols. Cells were 
electroporated using Nucleofector Program Q-001 in a 100 μL Amaxa cuvette.  
4.5.7 Confocal Microscopy 
Confocal microscopy of fixed K562 cells and HEK-293 cells was done using the 
Zeiss LSM 700. The K562 and HEK-293 cells were stained with Hoechst nucleus stain 
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(405 nm excitation and 300-629 nm detection) per manufacturer protocol. After processing, 
cells were fixed with 4% PFA, resuspended in imaging buffer (RPMI-1640 plus 1 mg/mL 
ascorbic acid), and mounted onto glass coverslips using clear nail polish for imaging. HEK-
293 cells were imaged with a 40X oil lens to analyze the expression of NLS-GFP and 
cGAS-mCherry. A 63X Apochromat oil lens was used to image fixed K562 cells delivered 
with Cy5-mRNA (639 nm excitation and 629-800 nm detection). Confocal microscopy of 
live cells with tetramethylrhodamine (TRITC)-dextran (555 nm excitation and 560-800 nm 
detection) was performed using the Zeiss LSM 700. The Zeiss 710 NLO with a 40X water 
lens was used to image live K562 cells with 100 nm nanoparticles (514 nm excitation and 
527-601 nm detection) (ThermoFisher) and live K562 cells stained with DiO membrane 
stain and Hoechst nucleus stain and delivered with Cy3-labled non-coding plasmid.  
4.5.8 Confocal Image Analysis 
Using Zen Lite software by Zeiss International, the raw fluorescence values from 
the Hoechst stain channel was exported as an 8-bit tag image file format (TIFF) image. The 
Hoechst image stacks were then imported into ImageJ and the fluorescence profile was 
modulated by a threshold intensity value of 20 to reduce background fluorescence. The 
outer edges of the stained areas were found, and using a circular profile estimator, the areas 
of the cell nuclei could be calculated for each layer. The cell area data was organized and 
averaged using MATLAB. Cells in which NLS-GFP has left the nucleus were identified 
by the presence of GFP fluorescence signal outside the Hoechst stained nucleus area. In 
determining the presence of a nuclear breach, the fluorescence data from the cGAS-
mCherry was modulated by increasing the multiplier for the intensity values for ease of 
viewing. Positive nuclear disruption was marked by small areas of higher intensity 
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mCherry fluorescence or marked by an outline of the nucleus by a ring of higher mCherry 
fluorescence intensity. Cells that presented these mCherry fluorescence signals were 
counted towards positive nuclear disruption and paired with the calculated average cell 
area for that cell. 
4.5.9 Protein Gel 
K562 cells were washed 3X with PBS (-/-) to remove serum protein and 
resuspended in serum-free RPMI-1640 at 2x106 cells/mL. For the Cell lysate control, cells 
were mixed with Halt™ Protease Inhibitor Cocktail, EDTA-Free (ThermoFisher), then 
underwent a 30-second liquid nitrogen snap freeze before thawing on ice for 10 minutes. 
The freeze-thaw process was repeated 5X. Cell lysate was centrifuged at 20,000xg for 15 
min at 15°C and the supernatant was collected. Cells were processed with 7 and 9.5 μm 
gap microfluidic devices, plus a No device control. Device and No device samples, 2.5 mL 
each, were centrifuged at 200xg. 1.5 mL of supernatant was collected and centrifuged 
again. Only 1 mL of supernatant was collected to avoid contamination from cell debris. All 
samples were mixed with protease inhibitor and then concentrated 10-fold using a 
Vivaspin® 5 kDa molecular weight cut-off spin concentrator (Sigma-Aldrich). Supernatant 
proteins were characterized by protein gel electrophoresis using pre-cast SDS-
polyacrylamide gel (Bio-Rad) according to manufacturer protocol. Sample loaded gel was 
run at constant voltage 200V. Gel was stained with SYPRO Ruby protein gel stain (Thermo 




4.5.10 Mass Spectrometry 
The proteins in each sample were reduced, alkylated and digested with trypsin 
according to the FASP protocol [51]. The peptides were analyzed by nano-LC-MS/MS, 
and peptide identification as previously described with the following modifications [52]. 
Reverse phase chromatography was performed using an in-house packed column (40 cm 
long X 75 μm ID X 360 OD, Dr. Maisch GmbH ReproSil-Pur 120 C18-AQ 1.9 µm beads) 
and a 120 min gradient. The Raw files were searched using the Mascot algorithm (ver. 
2.5.1) against a protein database constructed by combining the human UniProt protein 
database (downloaded April 24, 2018, 20,303 entries), and a contaminant database (cRAP, 
downloaded 11-21-16 from http://www.thegpm.org) via Proteome Discoverer 2.1. Only 
peptide spectral matches with expectation value of less than 0.01 (“High Confidence”) 
were used.    
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CHAPTER 5. APPLICATIONS FOR CELL ENGINEERING 
5.1 Introduction 
The field of cell engineering is experiencing rapid growth due to the development of 
cell-based immunotherapies. Cell engineering techniques are used to modify or analyze the 
cell physiological state for diagnostic or therapeutic applications. Intracellular delivery and 
analysis of intracellular molecular probes allows for characterization of cell physiological 
processes. Gene expression probes delivered to the intracellular space allow for analysis of 
gene expression in live cells that does not rely on cell surface expression [1,2]. 
Modification of the cell physiological state can occur through transient transfection of cells 
through the delivery of plasmids and mRNA that cause temporary expression of an 
exogenous gene without altering the cell genome. Permanent modification of cell gene 
expression can be achieved through the delivery of gene editing reagents [3-6]. Overall, 
methods to analyze cell physiological processes and modify cell gene expression are 
invaluable tools for cell engineering. The demand for these techniques continues to grow 
as the field of cell engineering expands in both research and clinical settings.  
Cell engineering techniques for modification and analysis of the cell state often 
require the intracellular delivery of large macromolecules, including plasmids, mRNA, 
nuclease complexes, and nanoparticle constructs. However, existing cell engineering 
techniques do not meet the growing demands for efficient processing of highly functional 
and viable cell products. The current standard approach is viral transduction, an expensive 
technique that has long-standing safety concerns [7-13]. The viral packing limits of the two 
most commonly used viral vectors are 5 kb for adeno-associated virus and 9 kb for 
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lentivirus [14,15], which impedes the application of viral transduction for next-generation 
cell therapies that require the delivery of larger genetic constructs and multiple gene edits 
[16,17]. Non-viral approaches such as electroporation are not effective for all molecule 
types of interest and can lead to inconsistent delivery with low viability and proliferation 
of cellular products, making this technique not ideally suited for cell therapy manufacture 
[9,18,19]. 
This thesis presents a convective mechanism, called cell VECT, for macromolecule 
delivery to cells to meet the growing demands of cell manufacturing and enable a new 
realm of applications for intracellular molecule delivery using microfluidics. During cell 
VECT processing, abrupt compressions cause the cell to change in shape and reduce in 
volume. Immediately following this brief cell volume loss, the cell automatically returns 
to its pre-compression shape and volume, causing the cell to uptake surrounding solution 
and any molecules suspended therein. This method utilizes this unique cell volume 
exchange phenomenon as a mechanism to deliver macromolecules into the cell on 
convective bulk flow currents, rather than diffusion alone. Cells processed using cell VECT 
have been shown to maintain high viability and proliferation [20,21].  
Therefore, convective intracellular delivery of large macromolecules using cell 
VECT has the potential to serve as a useful platform for various cell engineering 
applications. These applications include intracellular gene expression analysis, temporary 
exogenous gene expression, and permanent endogenous gene editing. In this aim, we will 
explore applications in intracellular labeling and analysis by delivering mRNA 
nanoparticle probes to analyze intracellular gene expression in living cells. We will also 
validate the application of cell VECT for both temporary and permanent gene expression 
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modification through the delivery of mRNA, plasmids, and gene editing reagents. Overall, 
our objective is to establish potential applications for cell VECT for various use cases in 
cell engineering.  
 
5.2 Intracellular Gene Expression Analysis 
A major application for intracellular molecule delivery is the analysis of gene 
expression in live cells. Current standard methods of analyzing intracellular gene 
expression require the cell to be lysed in order to extract DNA, RNA, or proteins for 
analysis. These methods are not capable of providing information on the localization of the 
gene expression or the trends in gene expression over time because the cell is no longer 
viable after processing [22,23]. Methods in which cells are fixed and permeabilized for 
intracellular gene labeling similarly cannot track temporal variation of gene expression 
[22,23]. Gene expression assays of live cells are typically limited to analysis of genes 
expressed on the cell surface, whereas the vast majority of genes are expressed in the cell 
interior. Therefore, methods for real-time analysis of intracellular gene expression in living 
cells are invaluable tools for the study of cell biology [22,23].  
Towards this objective, a family of RNA-based probes called nano-flares have been 
developed for intracellular analysis of RNA expression in live cells [1,2,22,23]. These 
nano-flare probes must be able to interact with the cell interior in an unencapsulated manner 
in order to access the cytosol and bind with their target RNA. Therefore, a non-endosomal 
method of delivering RNA probes would be advantageous for real-time labeling and 
analysis of intracellular RNA in live cells. We tested the cell VECT platform’s potential 
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applications for intracellular labeling and analysis of gene expression by delivering 
SmartFlare Live Cell RNA probes (Millipore). The SmartFlare is a type of RNA-based 
nanoflare probe that consists of a gold nanoparticle conjugated with oligonucleotides and 
quenched fluorophores. When the SmartFlare binds its target mRNA, the fluorophore is 
released as a fluorescent indicator of target mRNA expression (Figure 5.1A) [1,2]. This 
method of gene expression analysis allows for detection of gene expression at the RNA 
level, and facilitates analysis of intracellularly expressed genes in living cells, unlike 
traditional surface labeling and cell lysate assays.  
Our experiments delivered SmartFlare probes to detect GAPDH mRNA in K562 
cells and adherent PC3 prostate cancer cells. Delivery of the SmartFlare probe to PC3 cells 
was competitive with the established method of 24 hr endocytosis, and was completed in 
less than 30 mins (Figure 5.1B). The rapid nature of cell VECT delivery allows for a more 
immediate readout of gene expression, rather than an overnight incubation. Furthermore, 
it has been shown that not all cells will endocytose SmartFlare particles. K562 cells, which 
do not uptake SmartFlare particles through endocytosis, showed successful delivery using 
cell VECT (Figure 5.1C). Our success in delivering to PC3 and K562 cells demonstrated 
this method’s robustness for delivery to both adherent and nonadherent cells, and cells that 
do not uptake this particle through endocytosis. These delivery capabilities would expand 
the applications of intracellular live-cell gene expression assays to a wider range of use 
cases and cell types.  
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Figure 5.1: Intracellular delivery of nano-flare RNA probes. (A) Schematic of the mode 
of function of nano-flares. A gold nanoparticle is conjugated to oligonucleotides and 
quenched fluorophores. When the oligonucleotides bind a target mRNA, the fluorophore 
is released as a fluorescent indicator of gene expression. Figure reproduced with permission 
from reference [1]. (B) Cell VECT device intracellular delivery of SmartFlare nano-flare 
RNA probes to PC3 cells was competitive with the established standard method of 24 hr 
endocytosis. (C) The cell VECT device successfully delivered SmartFlare to K562 cells, 
which do not endocytose SmartFlares, which enables this probe to be usable with cells 
regardless of endocytic properties. Cells were processed with SmartFlare concentration of 
100 pM.   
 
An additional failure mode of nanoparticle-based intracellular probes that are 
delivered by endocytosis  is endosomal degradation. Degradation of the nano-flare can 
result in fluorescent signal release even without binding of the target mRNA, resulting in 
a false positive fluorescent readout that can compromise the accuracy of this gene 
expression assay [24,25]. This degradation results in a scramble control readout that has 
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the same intensity profile as the target mRNA readout (Figure 5.2A). The non-endosomal 
nature of cell VECT delivery allows the delivered particles to interact with mRNA in the 
cytosol without the need to escape the primary endosome. Therefore the fluorescent probe 
is not degraded due to cell VECT delivery, resulting in a target mRNA readout signal that 
is higher than the scramble control (Figure 5.2B). Furthermore, the fluorescent readout is 
detectable immediately after delivery with cell VECT, whereas endocytosis must be 
analyzed 24 hrs later.  
 
Figure 5.2: Non-endosomal delivery of nano-flare RNA probes prevents probe 
degradation. (A) Endosomal delivery of SmartFlare RNA probes results in probes being 
detained and degraded in the endosomes, causing a Scramble control signal that is 
indistinguishable from the gene readout signal (GAPDH). (B) Non-endosomal delivery 
using cell VECT results in SmartFlare localization to the cytosol, which avoids endosomal 
degradation and results in a Scramble control signal that is significantly lower than the 
GAPDH gene readout signal. Cells were processed with SmartFlare concentration of 100 
pM.   
 
5.3 Modification of Cell Gene Expression  
Modification of cell gene expression is vital for both the study of various cell 
processes and the manufacture of life-saving cell therapies. Cell engineering techniques to 
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modify cell gene expression profile can have temporary effects, through the delivery of 
transiently expressed mRNA or plasmids, or permanent effects through genome editing. 
The various cell engineering techniques, both temporary and permanent, usually require 
the delivery of reagents for cell transfection or gene editing, which are often large 
molecules such as plasmids or mRNA. The use of cell VECT for research and clinical 
applications can address important limitations of other microfluidic delivery platforms, 
particularly those that primarily use diffusive transport. Since diffusive transport is limited 
in the size of molecules that it can efficiently deliver, this presents a challenge in delivering 
these large cell engineering reagents. Convective transport does not have the size 
limitations inherent to diffusive transport [20,21,26], and is therefore a more efficient 
driving mechanism for the delivery of larger macromolecules for cell engineering. 
5.3.1 Temporary transfection through delivery of mRNA and plasmid 
Intracellular delivery of mRNA can be used to study and transiently express 
exogenous genes. Transfection using mRNA results in gene expression that is independent 
of cell cycle and has a more immediate gene expression readout than plasmid, since the 
mRNA can be directly translated and expressed in the cytoplasm without entering the 
nucleus. Unlike plasmid, expression of the gene encoded in the mRNA can easily be tuned 
by adjusting the amount of mRNA delivered [10]. Intracellular delivery of mRNA is also 
useful in immunotherapy applications, including loading dendritic cells with tumor 
antigens encoded in mRNA as a form of vaccination to elicit a targeted T-cell response 
[27].  
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To demonstrate the capabilities of cell VECT as a delivery platform for mRNA, we 
successfully delivered EGFP mRNA (TriLink) to K562 cells as a proof of concept 
experiment for transient expression of an exogenous gene (Figure 5.3A). The delivered 
EGFP mRNA construct measured 996 bases in length, or approximately 320 kDa in mass, 
which demonstrates the ability of cell VECT to deliver large macromolecules that will 
function and influence gene expression in the cell. We also successfully transfected 
primary peripheral blood mononuclear cells (PBMCs) with EGFP mRNA (Figure 5.3B). 
By demonstrating transfection in primary PBMCs, we exhibit the ability of cell VECT to 
successfully process a primary, heterogeneous cell population that is of therapeutic 
relevance.  
 
Figure 5.3: Transient exogenous gene expression by mRNA delivery. (A) Fluorescent 
expression signal of EGFP in K562 cell line following delivery of EGFP mRNA. K562s 
were processed in a microfluidic device with 9 μm compression gap. (B) Expression of 
EGFP in primary PBMCs delivered with EGFP mRNA. PBMCs were processed in a 




Transfection through intracellular delivery of non-integrating plasmids is another 
method of temporary transfection. These non-integrating plasmids must enter the nucleus 
in order for the encoded genes to be expressed, which results in a longer lead time to 
expression. However, gene expression using transfected plasmids can persist for several 
days longer than that of transfected mRNA [10]. We validate the application of cell VECT 
for temporary plasmid transfection by delivering EGFP plasmid (OZ Biosciences) (Figure 
5.4). We demonstrated gene expression of EGFP in K562 cells after delivery of an EGFP 
plasmid that is 5781 basepairs in length, or approximately 3,500 kDa in mass. This result 
exhibits the ability of cell VECT technology to deliver very large and functional cargoes 
that influence cell gene expression, a useful capability for both clinical and research 
settings.  
We do note that EGFP expression through plasmid delivery is lower than that 
observed by EGFP mRNA delivery. This is likely because plasmid must reach the cell 
nucleus in order to be expressed. We determined that cell VECT has minimal impact on 
nuclear envelop integrity [21]. Therefore, the delivered plasmid can only access the nucleus 
when the nuclear envelop is disrupted during cell division, which could result in a lower 
EGFP expression for the delivered plasmids.  
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Figure 5.4: Transient exogenous gene expression by plasmid delivery. EGFP 
expression proof of concept results after EGFP plasmid delivery to K562 cells. K562s were 
processed in a microfluidic device with 9 μm compression gap, 60 μg/mL EGFP plasmid, 
at 200 μL/min flow rate. 
 
5.3.2 Permanent Endogenous Gene Knockout 
Permanent modification of cell gene expression can be achieved through the 
intracellular delivery of genome editing reagents, such as CRISPR-Cas9 complexes. 
CRISPR-Cas9 was discovered in bacteria, which use clustered regularly interspaced short 
palindromic repeat (CRISPR) DNA sequences retained from previous bacteriophage 
infections to recognize and cleave viral DNA to prevent new infections [28-30]. This 
discovery was adapted into the CRISPR-Cas9 gene editing technology, wherein the 
CRISPR associated protein 9 (Cas9) nuclease is complexed to a guide RNA (gRNA) to 
form the CRISPR-Cas9 ribonucleoprotein (RNP) complex. The gRNA targets the RNP 
complex to a specified DNA sequence, and the Cas9 nuclease cuts at this location to 
permanently disrupt the encoded gene [28-30].  
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To demonstrate the gene editing capabilities of cell VECT, we used our 
microfluidic device to deliver precomplexed CRISPR-Cas9 RNPs for permanent knockout 
of a target gene. We chose the Jurkat T-cell line as a surrogate for primary T-cells, which 
are the main cell type of interest for cell-based immunotherapies. We selected the T-cell 
receptor alpha chain (TRAC) locus as the gene editing site. The TRAC locus is a gene 
editing site of interest for both CAR T-cell and TCR therapies. Targeted insertion of the 
CAR gene at the TRAC locus has been shown to improve tumor rejection in CAR T 
therapies [31]. Techniques for knocking out the endogenous T-cell receptor gene are of 
interest for the developing fields of TCR therapies and allogeneic T-cell therapies. 
Permanent silencing of the endogenous TCR genes prevents unpredictable interactions 
with the exogenous TCR, and lack of endogenous TCR expression can also attenuate the 
graft-vs-host response [32-35].  
To form the CRISPR-Cas9 RNP, the NLS-Cas9 nuclease (Aldevron) was 
precomplexed to a gRNA sequence (IDT) targeting the TRAC locus. The RNP was 
delivered to Jurkat cells using a 3.5 μm gap microfluidic device. We demonstrated 
successful knockout of the TRAC locus in Jurkat cells using analysis by TCR α/β antibody 
staining and flow cytometry (Figure 5.5A). Passing the cells through the microfluidic 
device multiple times only marginally improved editing efficiency (Figure 5.5A). Gene 
editing results were confirmed using Sanger sequencing (Error! Reference source not f
ound.5B). Using a smaller microfluidic compression gap was shown to significantly 
increase the device gene editing efficiency (Figure 5.5C).  
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Figure 5.5: Gene editing of the TRAC locus by CRISPR-Cas9 RNP delivery. (A) Jurkat 
cells stained with TCR α/β antibody show significant loss of TCR expression in device-
processed cells. Processing the cells through the device multiple times (3X) only 
marginally impacted TCR expression. (B) TRAC locus gene editing was confirmed using 
Sanger sequencing and indel analysis. No Device cells were exposed to the TRAC locus 
RNP but not processed by the device. N = 3, bars represent SD, *P<0.0001. (C) Processing 
cells using a smaller microfluidic compression gap resulted in increased loss of TCR 
expression, as determined by TCR α/β staining and flow cytometry. N = 3, bars represent 
SD, *P<0.05. 
 
Furthermore, cell VECT processing is shown to have minimal impact on viability 
and proliferation, even at high rate and magnitude of compression. Cells experience <10% 
change in viability compared to No device controls, and proliferation continues par with 
No device controls for several days after processing, doubling approximately once per day. 
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In contrast, cells that undergo gene editing by electroporation show a significant decrease 
in cell viability and proliferation (Table 5.1).  
 
Table 5.1: Table of cell VECT viability, proliferation, and editing vs electroporation. 
Electroporation has significantly lower viability and proliferation compared to cell VECT 
and untreated controls. In contrast, cell VECT samples maintain viability and proliferation 
comparable to untreated controls, doubling approximately once per day. Therefore, cell 
VECT has a higher edited cell ROI than electroporation despite having lower editing 
efficiency. Viability normalized to negative control. Mean ± SD, N = 3.  
 
The combination of maintained viability and rapid proliferation enables cell VECT 
to produce a larger number of gene-edited cells than electroporation after a 5-day expansion 
period, despite electroporation producing a higher gene editing percentage. We can 
consider each gene editing technique as a system that takes a given input, a particular 
amount of CRISPR-Cas9 RNP and cells for processing, and produces gene-edited, viable 
cells as its output. The cell VECT system produces a higher return on input (ROI) for viable 
gene edited cells than electroporation due to higher cell viability and proliferation (Figure 
5.6A,B). High viability and expansion are both important properties for cell therapy 
manufacturing, since engineered immunotherapy cells must usually be expanded to a 
therapeutic dose of at least 1 billion cells for an adult patient, and must maintain high cell 
viability to avoid adverse effects [36-38].  
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Figure 5.6: Cell VECT edited cell ROI compared to electroporation. (A) A schematic 
explanation of edited cell ROI. For a given number of input cells, the electroporation 
method produces a higher percentage of edited cells (purple). However the cell VECT 
population exhibits higher viability and proliferation over 5 days, resulting in a larger total 
population of edited cells. Note the post-proliferation population only shows gene edited 
cells, but the overall gene editing percentage remains the same as the pre-proliferation 
population. The total number of edited cells is a product of  cell viability, proliferation, and 
gene editing efficiency. The edited cell ROI metric is the number of gene edited cells on 
Day 5 divided by the number of total input cells on Day 0. (B) Edited cell ROI of cell 
VECT exceeds electroporation due to higher viability and proliferation. N = 3, bars 
represent SD, *P<0.0001.  
 
5.3.3 Multiplexed Endogenous Gene Editing 
With the validation of cell VECT for permanent gene editing, we next sought to 
further apply this delivery platform for multiplexed gene editing. Multiplexed gene editing 
requires the delivery of multiple gene editing reagents to target different gene editing sites. 
Techniques for multiplexed gene editing are of great interest in many cell engineering use 
cases, particularly in cell therapies. Many cell therapies currently in preclinical and clinical 
development use multiple gene edits to target disease indications that cannot be effectively 
targeted by cell therapies that were created using a single gene edit. A powerful example 
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is in the treatment of T-cell acute lymphoblastic leukemia (T-ALL), which accounts for 
~15% of all pediatric ALL and 25% of all adult ALL [33]. While certain T-cell surface 
markers, such as CD5 and CD3, can be used to target T-ALL using CARs, T-cell 
malignancies remain difficult to treat using single-edit CAR T-cell therapies due to the 
occurrence of T-on-T killing, or fratricide [33,39,40]. Therefore, a CAR T-cell that targets 
CD5 to treat T-cell malignancies must also undergo knockout of the endogenous CD5 gene 
to prevent fratricide. 
Another invaluable application for multiplexed editing in cell therapies is motivated 
by the high demand for allogeneic cell therapies. The current dependence of clinical cell 
therapies on autologous cells poses a substantial cost, logistical, and manufacturing burden 
[41-43]. Furthermore, many patients are not able to provide usable T-cells for autologous 
treatment due to advanced disease state or chemotherapy effects, making them ineligible 
for life-saving cell therapies [43]. Knockout of endogenous TCR expression has been 
shown to enable the use of allogeneic T-cell therapies without provoking the graft-vs-host 
immune response [34]. Therefore, the implementation of multiplexed gene editing for cell 
therapy manufacturing facilitates a wide range of new cell therapy use cases and treatment 
targets.  
In our experiments, we aimed to perform permanent gene knockout of the TRAC 
locus and the CD5 gene, a combination that would potentially enable the development of 
an allogeneic T-cell therapy that targets T-ALL. We used the cell VECT platform for 
simultaneous delivery of two species of CRISPR-Cas9 RNPs to target both editing sites in 
a single delivery. Flow cytometry analysis of antibody staining of TCR and CD5 showed 
successful knockout of both genes in ~10% of processed cells (Figure 5.7).  
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Figure 5.7: Multiplexed editing of CD5 and TRAC locus by CRISPR-Cas9 RNP 
delivery. (A) Jurkat cells stained with mouse IgG1 isotype controls to define double 
negative antibody stain gating. (B) No device control exposed to both CD5 and TRAC 
RNP without device processing and stained with CD5 and TCR α/β antibody. (C) Jurkat 
cells processed with cell VECT and both CD5 and TRAC RNP and stained with CD5 and 
TCR α/β antibody show a subpopulation of successful double knockout of CD5 and TCR 
expression in device-processed cells.  
 
 
Table 5.2: Table of cell VECT double-editing, viability, and proliferation vs 
electroporation. As with single-editing, cell VECT maintains higher cell viability and 
proliferation than electroporation, resulting in a higher viable double-edited cell ROI than 
electroporation despite having lower double editing efficiency. Viability normalized to 
negative control. Mean ± SD, N = 3.  
 
Similar to the single-knockout gene editing experiments, cells subjected to 
multiplexed gene editing in the cell VECT device maintained high viability and 
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proliferation, whereas cells that underwent multiplexed gene editing by electroporation had 
significantly lower viability and proliferation, but higher double-editing efficiency (Table 
5.2). Overall, the viable double-edited cell ROI was higher in cell VECT cells than 
electroporation due to higher proliferation and viability (Figure 5.8).  
 
Figure 5.8: Cell VECT double-edited cell ROI compared to electroporation. ROI of 
multiplexed gene editing for cell VECT exceeds electroporation due to higher viability and 
proliferation. N = 3, bars represent SD, *P<0.05.  
 
5.4 Summary of cell VECT applications for cell engineering 
The rapidly growing field of cell manufacturing requires robust methods for 
intracellular delivery of macromolecule reagents for cell engineering and analysis. 
However, this field still lacks an intracellular delivery platform that is cost-effective, 
maintains high cell viability, and is broadly applicable for diverse cargoes and cell types. 
We utilize the unique biophysical phenomenon of mechanically-induced cell volume 

























in intracellular gene analysis, temporary transfection, and gene editing demonstrate great 
potential for cell VECT to address major challenges in cell manufacturing.  
The ability of cell VECT to deliver large macromolecules facilitates the intracellular 
delivery of high molar mass reagents for transfection and gene editing. We have 
demonstrated proof-of-concept results using EGFP mRNA and plasmid for temporary 
transfection of cell lines and primary cells. We validate the use of cell VECT for gene 
editing by delivering CRISPR-Cas9 RNP complexes for permanent knockout of the TRAC 
locus. We further utilize the ability of cell VECT to deliver multiple cargoes by 
successfully demonstrating multiplexed gene editing of the TRAC locus and CD5 genes 
by simultaneously delivering two CRISPR-Cas9 RNP constructs.  
Our transfection experiments also revealed some of the limitations faced by cell 
VECT in comparison to established electroporation techniques. We observed that 
electroporation achieved higher EGFP expression than cell VECT when delivering EGFP 
mRNA and plasmid. In our gene editing studies, we aimed to compensate for this factor by 
optimizing intracellular delivery with higher magnitude compressions and faster flow rates, 
which were facilitated by glass-reinforced devices. Gene editing efficiency using cell 
VECT was improved after optimization, but remained lower than electroporation for the 
same cell and reagent concentrations. These findings suggest that electroporation, or 
possibly the electrophoretic delivery driving mechanism, is able to achieve higher 
intracellular delivery concentration with less limitation due to extracellular reagent 
concentration.   
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Macromolecule delivery using cell VECT enables a number of useful applications 
for intracellular analysis. The nonendosomal delivery allows unencapsulated delivered  
molecules to interact directly with the cell interior, which enables the delivery of 
intracellular gene expression probes, like nano-flare mRNA probes, directly to the cytosol 
without the need to escape an endosome. The rapid nature of delivery while maintaining 
cell viability allows the nano-flares to directly bind target mRNA for a more immediate 
readout of gene expression in live cells, which is not possible with standard methods of 
intracellular analysis that require cell lysis or fixation  
Overall, these results in a wide array of useful applications in intracellular gene 
expression analysis, temporary transfection, and permanent and multiplexed gene editing 
validate several highly valuable use cases for cell VECT in cell manufacturing and open 
the doors to many more applications.  
 
5.5 Additional Applications 
Further applications of interest have included using cell VECT for intracellular 
delivery of proteins for in-cell nuclear magnetic resonance (NMR) spectroscopy, and 
labeling stem cells for in-vivo therapeutic cell tracking. These applications have been 
explored through collaborations with laboratories at other institutions. In-cell NMR is 
being studied in collaboration with Alexander Shekhtman’s lab at State University of New 
York at Albany. Stem cell labeling for in-vivo tracking is being studied in collaboration 
with Heike Daldrup-Link’s lab at Stanford University.  
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In-cell NMR protein spectroscopy allows for the characterization of protein 
structure and interactions in the intracellular environment to help reveal protein signaling 
pathways [44,45]. However, in order to detect a target protein using in-cell NMR, the target 
signal must be distinguished from the background signal of other cell proteins, which 
requires the target protein concentration to exceed typical physiological levels [44,45]. 
Therefore, the field of in-cell protein NMR requires efficient methods for intracellular 
delivery of the target proteins. The delivery characteristics of cell VECT are advantageous 
for in-cell NMR applications. Since cell VECT delivers directly to the cell cytosol, the 
delivered protein does not face the additional impediment of escaping a primary endosome 
in order to reach its target interaction site.  
 We demonstrate the application of cell VECT for intracellular delivery of target 
proteins for in-cell NMR protein spectroscopy. For this study, we delivered dopamine- and 
cAMP-regulated neuronal phosphoprotein (DARPP-32) to HeLa cervical epithelial cells. 
DARPP-32 is a neuronal phosphoprotein that is part of the dopamine signaling pathway 
and has been shown to be decreased in the leukocytes and prefrontal cortex of the brain in 
patients with schizophrenia and bipolar disorder [46-49]. Therefore, a detailed study of the 
protein interactions and signaling cascade in the dopamine signaling pathway would grant 
a stronger understanding of dopamine signaling abnormalities and the associated 
psychiatric diseases. DARPP-32 delivered using cell VECT can then be analyzed by in-
cell NMR and western blot to determine DARPP-32 presence and locations of 
modifications that impact protein function, such as phosphorylation (Figure S5. 1).  
Labeling therapeutic stem cells for in vivo imaging allows for long term tracking of 
cell localization and regenerative progression. However, existing methods for intracellular 
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labeling require lengthy laboratory processing, which poses potential contamination risks 
[50] and can potentially impact stem cell physiology and potency [51-53]. Furthermore, 
because the labeling process usually takes several hours, it is impractical for stem cells to 
be harvested, labeled, and transplanted in a single surgery. We investigated the application 
of cell VECT as a method of rapid stem cell labeling to facilitate a single surgical procedure 
in which stem cells can be harvested, labeled with a contrast agent, and transplanted to 
track stem cell localization and engraftment without impacting treatment outcomes (Figure 
S5. 2A) [54].  
Delivery of multiple contrast agents allows for cell tracking and detection using 
multiple imaging modalities: positron emission tomography (PET) and magnetic resonance 
imaging (MRI). For this study, we labeled and tracked adipose tissue-derived stem cells 
(ADSCs), which are used in regenerative medicine to treat degenerative joint diseases and 
cartilage defects. We used cell VECT to deliver ferumoxytol nanoparticles to the ADSCs 
for tracking using MRI (Figure S5. 2B) [54]. We simultaneously delivered a second tracer 
molecule, 18F-fluorodeoxyglucose (FDG), for cell tracking using PET (Figure S5. 2C) 
[54]. This multimodal labeling and imaging allows for quantification of ADSC delivery 
and engraftment in the disease site using PET, with long term cell tracking and observation 
using MRI. Delivery of both ferumoxytol and FDG labeling agents can be done using cell 






5.6.1 Fabrication of Microfluidic Channels  
The microfluidic features of this device were molded onto polydimethylsiloxane 
(PDMS) and plasma bonded to a glass slide. A reusable SU-8 mold was made using 
standard two-step photolithography on a silicon wafer. To fabricate the devices, a 10:1 
ratio of PDMS and crosslinking agent was mixed and poured onto the SU-8 mold to form 
the microfluidic channel features by replica molding. For permanent gene editing devices, 
a glass slide was embedded into the PDMS. The PDMS was then degassed in a vacuum 
chamber and cured for 1 hr at 80°C. The cooled PDMS was then removed from the molds 
and outlets and inlets were punched using biopsy punches. The PDMS was then bonded to 
clean glass slides using a plasma bonder (PDC-32G Harrick) followed by 1 hr in a 80°C 
oven. After cooling, the channels were passivated using sterile filtered 1% bovine serum 
albumin (BSA) in DI water. For more detailed device fabrication protocols, please see 
Appendix A.1.  
 
5.6.2 Microfluidic Experimental Setup  
For SmartFlare RNA probe delivery experiments, cells were resuspended in serum-
free RPMI-1640. For transfection and gene editing microfluidic experiments, cells were 
resuspended in Opti-MEM before flowing through the device. The cells were isolated from 
culture media and resuspended in buffer at ~1-10x106 cells/mL with the desired 
concentration of target molecules. The cell-buffer suspension was infused into the 
microfluidic device at a controlled rate using syringe pumps (PHD 2000, Harvard 
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Apparatus). For delivery of constitutively fluorescent molecules, following collection from 
the outlets, the cells were washed 2X with 10-fold volume DPBS (-/-) to remove residual 
molecules external to the cells before analysis. Cells transfected with mRNA were analyzed 
at 12, 24, and 48 hour time points following transfection, with peak expression at 12 hours. 
Cells transfected with plasmid were analyzed at 24, 48, 72, and 96 hours following 
transfection, with peak expression at 24 hours. For experiments in which cells were 
cultured following microfluidics, the microfluidic experiment was conducted inside a 
sterile biosafety cabinet. All cell-handling supplies, including the device, syringe, and 
needles, were sterilized by autoclaving. For more detailed microfluidic experimental 
protocols, please see Appendix A.1. 
5.6.3 Cell Culture 
K562 cells from ATCC were cultured in RPMI-1640 supplemented with 10% fetal 
bovine serum (FBS) and 1% penicillin-streptomycin. PC3 prostate cancer cells (CRL-
1435), a gift from BD Biosciences, were cultured in F-12K with 10% FBS and 1% 
penicillin-streptomycin and passaged using 0.25% Trypsin-EDTA. Deidentified and 
discarded blood sample was collected from Lam Lab, Georgia Institute of Technology, 
under an institutional review board (IRB) approved study for laboratory research on 
discarded clinical samples and all methods were performed in accordance with the relevant 
guidelines and regulations. Primary leukocytes were isolated from whole donor blood by 
density gradient centrifugation. Whole donor blood was centrifuged at 700 RCF for 10 
mins with Ficoll density centrifugation media and the concentrated leukocyte band (buffy 
coat) was collected. Primary T-cells were isolated from healthy donor leukapheresis 
product using the EasySep Human T cell Enrichment Kit (Stem Cell Technologies) 
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according to manufacturer protocol. Primary T-cells were cultured in TexMACS medium 
(Miltenyi Biotec) with 100 IU/mL IL-2 (Miltenyi Biotec) and activated with T Cell 
TransAct (Miltenyi Biotec) CD3/CD28 nanoparticle T-cell activator at a 1:1 T-cell: 
nanoparticle ratio. Experiments took place 2 days after T-cell activation. Jurkat cells from 
ATCC were cultured in RPMI-1640 supplemented with 10% fetal bovine serum (FBS), 
1% L-glutamine, and 1% penicillin-streptomycin. The cells were incubated at 37°C with 
5% CO2. 
5.6.4 CRISPR-Cas9 RNP Gene Editing 
The Cas9 nuclease was precomplexed to a gRNA sequence targeting the TRAC 
locus (IDT) to form the CRISPR-Cas9 RNP. We used  the following CRISPR-Cas9 gRNA 
sequence for TRAC locus editing which has been previously published and validated: 
AGAGTCTCTCAGCTGGTACA [31]. To form the RNP, the Cas9 was mixed with a 2.5 
molar excess of gRNA and incubated at room temperature for 30 mins. To promote 
localization of the RNP to the nuclease for gene editing, we used a Cas9 nuclease 
conjugated to a nuclear localization signal (NLS) (sNLS-SpCas9-sNLS Nuclease, 
Aldevron). Cells were processed using a microfluidic device with 3.5 μm compression gap 
and glass reinforcement in Opti-MEM with at 800 μL/min with 100 μg/mL NLS-Cas9 plus 
2.5 molar excess gRNA. For multiplexed gene editing experiments, we precomplexed each 
species of RNP individually. For each multiplexed gene editing cell sample, we prepared 
100 μg/mL NLS-Cas9 plus 2.5 molar excess gRNA for both TRAC and CD5, doubling the 
overall amount of CRISPR-Cas9 RNP. The two species of RNP were combined with cells 
immediately before processing with microfluidics or electroporation. Gene expression was 
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analyzed with flow cytometry after 5 days. Gene editing was analyzed by Sanger 
sequencing.  
5.6.5 DNA Sequencing 
Genomic DNA from the CRISPR-Cas9 gene editing experiments were isolated 
using QuickExtract DNA Extraction Solution (Lucigen) according to manufacturer 
protocol five days after delivery experiments. The genomic DNA was amplified using 
Phusion High-Fidelity PCR Master Mix (New England BioLabs) according to 
manufacturer protocol. The following primers were used to amplify the TRAC locus cut 
site: TGC CTG CCT TTA CTC TGC CA (forward) and AGG CCG AGA CCA ATC AG 
(reverse). Amplification was determined by gel electrophoresis. The PCR products were 
purified and then analyzed by Sanger sequencing (Eton Bioscience) and TIDE software 
was used for indel analysis.  
5.6.6 Flow Cytometry 
Flow cytometry was performed using the BD Accuri C6 Flow Cytometer and 
FlowJo analysis software. Cell uptake of cyanine-3 SmartFlare RNA probes was analyzed 
using 488 nm excitation and 585/40 filter. Expression of GFP RNA or plasmid was 
analyzed using 488 nm excitation and 533/30 filter. Cy5 delivery was analyzed using 640 
nm excitation and 670 long pass filter. TCR expression was analyzed by staining with 
Alexa Fluor 488 anti-human TCR α/β antibody (488 nm excitation and 585/40 filter) 
(BioLegend) according to manufacturer protocol. 7-AAD (BioLegend) was used per 
manufacturer protocol to exclude nonviable cells (488 nm excitation and 670 long pass 
filter). CD5 expression was analyzed using PE anti-human CD5 antibody (488 nm 
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excitation and 585/40 filter) (BioLegend). Multiplex antibody staining was done using 
Helix NP NIR (BioLegend) viability stain exclusion and compensation to minimize 
fluorescent channel crosstalk.  
5.6.7 Statistical Analysis 
GraphPad Prism and Microsoft Excel were used to perform statistical analysis 
(ANOVA and t-test) and generate plots.  
5.6.8 Electroporation 
Electroporation of Primary T-cells was carried out using an Amaxa Nucleofector II 
and Lonza Human T Cell Nucleofector Kit using manufacturer protocols. T-cells were 
electroporated using Nucleofector Program T-023 in a 100 μL Amaxa cuvette. Jurkat cells 
were electroporated using Lonza Cell Line Nucleofector Kit V using manufacturer 
protocols. Jurkat cells were electroporated using Nucleofector Program X-001 in a 100 μL 
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5.8 Supplemental Information 
 
 
Figure S5. 1: Schematic of intracellular protein delivery and analysis. Suspended cells 
combined with purified protein are infused into the microfluidic device. The protein-loaded 
cells are then analyzed for viability (bottom left-most) and can then be characterized by 
(left to right) in-cell NMR, fluorescence microscopy, and western blot to determine protein 




Figure S5. 2: Schematic and characterization of multimodal stem cell labeling. (A) A 
heterogeneous cell population containing ADSCs is harvested from the pre-patellar fat pad. 
ADSCs are concentrated and then undergo labeling with two different types of tracer 
molecules, ferumoxytol nanoparticles and FDG radiotracer, simultaneously by cell VECT 
before implantation into the cartilage defect. (B) Flow cytometry of ADSCs labeled with 
FITC-labeled ferumoxytol particles shows successful delivery to >95% of processed cells. 
(C) Delivery of FDG radiotracer to ADSCs using cell VECT is significantly higher than 
conventional co-incubation when characterized by in vitro PET imaging of plated cells. 
Cells were processed using microfluidic devices with a 9.6 μm compression gap, with 10 
mg/mL ferumoxytol and 57 MBq/mL 18F-FDG.  
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CHAPTER 6. CONCLUSIONS AND OUTLOOK 
6.1 Summary of Major Findings 
6.1.1 Aim 1: Characterizing governing parameters of cell VECT 
By using microfluidics to precisely induce rapid, brief, large strain compressions, 
we elucidated the surprising phenomenon of temporary cell volume exchange that 
facilitates intracellular delivery of external macromolecules. We discovered a behavior 
wherein cells initially undergo sudden volume loss followed by fast volume recovery. We 
found that induced volume loss is greater for faster compressions caused by higher flow 
rates and larger strains imposed through smaller constrictions. We report the Ericksen 
number as a dimensionless parameterization of compression rate and cell viscoelastic 
properties that can predict the resulting cell volume loss. This relation may inform the 
implementation of cell VECT for a wide variety of human cell types. We also found that 
increased intracellular delivery required multiple ridges spaced such that there was 
sufficient time for cells to recover lost volume between each ridge. We used this effect of 
volume change and relaxation as a new approach to deliver molecules to cells. Specifically, 
rapid compression-driven volume loss worked in conjunction with cell relaxation to 
convectively drive volume and molecules into the cell interior.  
The physical cause of this surprising cell behavior can be explained by considering 
the relevant forces imposed on the cell by the ridges. The sudden inertial compression 
under a ridge with stepwise profile is equivalent to a high velocity (~1 m/s) vertical impact 
on the cell to disrupt the membrane in a manner akin to a droplet splatter upon a surface. 
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The subsequent physical constriction of the cell under the ridge results in rapid transfer of 
momentum to the liquid of the cell interior to drive fluid volume out of the cell. The brief 
nature of this compression causes cells to relax on a rapid time scale to uptake volume after 
compression. The observed rapid recovery is consistent with rapid, poroelastic recovery 
behavior of the cytoplasm at short time scales (<0.5 s) after brief compression [1,2].  
Overall, the phenomenon of cell VECT can be summarized into the following steps: 
(1) cell volume loss during rapid compression, (2) cell uptake of surrounding volume and 
target molecules during recovery, and (3) repetition of compressions for maximum 
intracellular delivery of target molecules. These steps are visualized and identified in 
Figure 6.1.  
 
Figure 6.1: Visualized summary of the cell VECT process. The process of cell VECT 
can be broken down into the following steps: (1) cell volume loss during compression, (2) 
convective molecule uptake during volume recovery, and (3) repeated compressions for 
maximum delivery. The cell membrane will subsequently reseal and retain delivered cargo. 
 
6.1.2 Aim 2: Defining intracellular delivery capabilities and physiological effects on 
cells 
In this aim, we defined the characteristics and capabilities of intracellular 
macromolecule delivery using cell VECT. Cell VECT was shown to be distinct from 
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current diffusive mechanoporation platforms, both in mechanism and capability. Diffusive 
microfluidic mechanoporation methods used gradual constrictions to impart shear stress on 
cells in a manner that facilitates smooth cell flow and thus slower deformation [2-7]. The 
constriction creates a shear force on the cell membrane leading to membrane poration and 
extracellular molecular diffusion into the cell interior. While diffusion is a universal 
transport mechanism, it imposes constraints on delivery due to the inverse relationship 
between diffusivity and molecule size. Indeed, diffusive approaches to microfluidic 
mechanoporation have shown limited efficiency in the delivery of large macromolecules 
[8-13]. We characterized a convective intracellular delivery mechanism that is 
nonendosomal and independent of molecule size. 
The purely mechanical, microfluidic approach avoids many of the prohibitive 
drawbacks and detrimental changes to cell physiology associated with using chemical, 
viral, or electrical processing [14-20]. This study finds that cell VECT causes minimal 
impact on nuclear envelop integrity and exchange of nuclear contents with the cytoplasm, 
which suggests that DNA damage does not occur. The ability of the cytoskeleton to 
regulate cell volume and retain solutes could explain the minimal impact of cell VECT on 
intracellular protein content despite the initial volume loss [21]. Long term cell viability 
and proliferation is also maintained, which supports the use of cell VECT in various useful 





6.1.3 Aim 3: Applications of cell VECT 
In our studies, we found cell VECT utilizes an advection-dominated molecular 
driving mechanism to efficiently deliver a wide range of macromolecules to various types 
of human cells. The simplicity of use and successful proof of concept experiments in 
transfection and intracellular labeling demonstrate potential to overcome the most 
prohibitive challenges in intracellular delivery for cell engineering applications.  
This work has validated cell VECT as a platform for intracellular labeling for cell 
analysis and tracking. Nonendosomal delivery of intracellular RNA probes enables real-
time analysis of gene expression in living cells. Intracellular delivery of proteins facilitates 
NMR spectroscopy that elucidates intracellular protein modification and signaling 
pathways. Labeling of therapeutic stem cells with a combination of imaging contrast agents 
allows for multimodal imaging for long-term spaciotemporal tracking of therapy 
progression in vivo. Stem cell labeling for multimodal imaging can be done during the same 
surgery as the stem cell extraction and transplant.  
The cell VECT platform can also be used to deliver reagents that modify cell gene 
expression, both temporarily and permanently. Delivery of non-integrating plasmid and 
mRNA demonstrated temporary expression of exogenous genes in cell lines and primary 
cells. Successful knockout of endogenous genes using CRISPR-Cas9 gene editing 
validated the application of cell VECT for permanent modification of gene expression. The 
results of cell VECT in cell labeling, analysis, and gene expression modification support 
the utility of this technology for useful applications in diagnostics and therapeutics.  
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6.2 Continuing Work 
The contributions of this research have enabled a number of useful potential 
applications using cell VECT. As a continuation of this thesis work, multiple projects will 
further explore cell VECT in several applications of potential significance in research and 
clinical settings. The gene editing capability will be combined with viral transduction to 
prevent self-killing in CAR T-cells targeted at T-cell malignancies. A continuation of this 
research will investigate multiplexed gene editing in immunotherapeutic cells using cell 
VECT. Another project will explore the use of cell VECT for gene editing replacement of 
the endogenous TCR with an exogenous TCR. A continuing project will study gene editing 
of retinal progenitor cells by delivering very large plasmids using cell VECT.  
 
6.2.1 Gene Knockout for CD5-targeting CAR T-cells 
While CAR T-cell therapies have been proven to be highly effective in inducing 
remission in hematological cancers, the primary efficacy of CAR T-cell therapies has been 
in the treatment of B-cell malignancies [22-26]. The implementation of CAR T-cell 
therapies for the treatment of T-cell malignancies is complicated by the occurrence of self-
killing, or fratricide, because a CAR construct targeted at T lymphoblasts will also direct 
cytotoxic activity against healthy T-cells and therapeutic CAR T-cells. T-cell acute 
lymphoblastic leukemia (T-ALL) accounts for ~20% of acute lymphoblastic leukemia and 
carries a poor prognosis, with a survival rate of <15% with conventional chemotherapy 
[27-30]. Only a minority of patients achieve remission and qualify for allogeneic 
hematopoietic stem cell transplantation (HSCT) [31], and even then the 3-year survival 
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rate after HSCT is ~50% [32]. Therefore, existing treatment methods for T-ALL would 
greatly benefit from the development of a viable CAR T-cell treatment option.  
The CD5 surface marker is a relatively reliable surface marker for T-cell 
malignancies and has been shown to be an invaluable targeting gene against T-ALL [33-
37]. However, CD5 is also expressed on healthy peripheral T-cells, thymocytes, and the B-
1 subpopulation of B-cells. Preclinical studies of CD5-targeting CAR T-cells have shown 
cytotoxic activity directed against T-ALL cells, but also healthy cells and other therapeutic 
cells, and overall diminished efficacy. These findings suggest that T-ALL treatment using 
CD5-CAR T-cells requires knockout of the endogenous CD5 gene in the therapeutic cells 
to prevent fratricide and improve treatment efficacy [33,34].  
An ongoing project in our lab combines non-viral CD5 knockout gene editing with 
viral expression of a CD5-CAR construct in primary T-cells. The T-cells are first processed 
with cell VECT to deliver a CRISPR Cas9 RNP construct for CD5 knockout. Processing 
with cell VECT enables permanent gene editing that maintains cell viability and 
proliferation for downstream processing with a lentiviral vector for transduction of the 
CD5-CAR gene. The therapeutic cells will be validated using in vitro cytotoxicity assays 
against T-ALL and in an in vivo T-cell leukemia xenograft mouse model. The sequential 
nonviral knockout and viral knock-in editing steps will result in a therapeutic CD5-
targeting CAR T-cell population that is CD5-negative, preventing fratricide and improving 




6.2.2 TCR Replacement via CRISPR Cas9 
The development of non-viral, targeted gene editing techniques is a field of growing 
interest in the cell therapy space. The current standard method, viral transduction, suffers 
from high manufacture costs and persistent concerns over insertional mutagenesis due to 
the random nature of viral editing [15-18,38-40]. Furthermore, results have shown that 
targeting the insertion site of the CAR gene to the TRAC locus significantly improves the 
anti-tumor cytotoxic activity of CAR T-cells [41]. During the manufacture of TCR 
therapies, knockout of the endogenous TCR receptor genes is a necessary step to prevent 
the formation of unpredictable dimers between the exogenous TCR gene and the 
endogenous TCR [42]. Therefore, a continuing project in our lab seeks to utilize cell VECT 
for targeted knockout of the endogenous TRAC gene coupled with HDR-mediated knock-
in of an exogenous TCR construct.  
The overall goal of this project is to validate the application of cell VECT for 
targeted replacement of an endogenous gene with an exogenous therapeutic gene. Primary 
T-cells will be delivered with CRISPR-Cas9 RNP targeting the TRAC locus, along with a 
homology-directed repair (HDR) template encoding an exogenous TCR gene. This process 
should result in the knockout of the endogenous TRAC locus gene and insertion of the 
exogenous TCR gene at that site. While this project would specifically demonstrate 
applications for TCR therapy manufacturing, the results have strong implications for the 
use of cell VECT for any targeted gene replacement application, including the treatment of 
genetic disorders through the non-viral correction of faulty genes.  
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6.2.3 Multiplexed Gene Editing for Next Generation Cell Therapies 
The next generation of cell-based immunotherapies require multiple gene edits to 
improve treatment safety and efficacy [30,43]. A major cause of disease relapse in cancer 
patients undergoing CAR T-cell therapy is a phenomenon called antigen escape, wherein 
a subpopulation of tumor cells that underexpress the targeted tumor antigen emerges, 
allowing the cancer to evade the CAR T therapy [44]. Therefore, next generation therapies 
aim to target multiple tumor antigens to prevent antigen escape. Furthermore, the overall 
trend of interest toward allogeneic, off-the-shelf cell therapies requires multiple gene edits 
to prevent graft-versus-host reactions. Specifically, inhibitory surface genes such as PD-1 
are knocked out to ensure persistence of the therapeutic cells, while the endogenous TCR 
genes are knocked out to diminish graft-versus-host disease due to the allogeneic cells. 
Therefore, as new cell-based immunotherapies are developed, the demand for multiplexed 
gene editing techniques grows. 
A continuing project in the Sulchek lab aims to utilize the ability of cell VECT to 
simultaneously deliver multiple cargoes in order to deliver multiple species of gene editing 
reagents for multiplexed gene editing. Primary T-cells will be processed with CRISPR 
Cas9 RNPs targeting PD-1 and both TCR genes (alpha and beta constant regions TRAC 
and TRBC). The ability to deliver multiple gene editing reagents without requiring 
additional processing steps allows this method to maintain high cell viability for 




6.2.4 Gene Engineering of Retinal Progenitor Cells using Large Plasmids 
In addition to the cell immunotherapy projects previously described, we also aim to 
apply cell VECT to engineer stem cells for regenerative medicine. Gene engineering of 
stem cells is a promising strategy for treating permanent blindness caused by inherited 
degenerative retinal diseases. Since these inherited retinal diseases are usually caused by a 
single genetic defect, gene correction using CRISPR-Cas9 can potentially reverse disease 
effects and restore vision. The current standard strategy for correction of genetic defects in 
inherited retinal diseases is to use adeno-associated virus (AAV) to insert the functional 
gene into the genome of patient photoreceptor cells [45-48]. Implementing this gene 
correction process in patient-derived induced pluripotent stem cells (iPSCs) enables an 
autologous treatment option for patients who have already sustained significant loss of 
photoreceptor cells. However, almost 25% of inherited retinal diseases require the delivery 
of genes that are several times larger than the 5 kb packaging limit of AAVs [49]. An 
example of one such gene is USH2A, which has a coding length of approximately 15 kb. 
Mutations in the USH2A gene are associated with blindness as part of Usher syndrome.  
Therefore, retinal therapeutics aimed at correcting blindness caused by USH2A 
defects would greatly benefit from an intracellular delivery method that can deliver very 
large genetic constructs. Preliminary experiments delivering large gene constructs (≥10 kb) 
show that cell VECT exceeds the transfection efficiency of lipofection, the current standard 
method for delivering plasmids that are too large for viruses to package. This ongoing 
project aims to optimize cell VECT delivery of large genetic constructs to produce gene 
corrected iPSCs. The focus will be on permanent correction of the USH2A gene by delivery 
of large plasmid constructs containing CRISPR-Cas9, the USH2A coding region, and an 
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antibiotic resistance selection gene. This project aims to utilize cell VECT’s large cargo 
delivery capability to facilitate gene correction therapy in inherited diseases caused by 
defects in large genes.  
 
6.3 Conclusions 
In this thesis, we characterized the cell biomechanical phenomenon wherein rapid, 
high strain compressions cause cell volume loss and recovery. We found that this cell 
volume exchange caused extracellular molecules to be driven into the cell interior by 
convection. We refer to this process as cell VECT, cell volume exchange for convective 
transfer. We have determined the device and experiment parameters that govern cell VECT 
and provide basic understanding to mechanically induced cell volume exchange. We use 
these findings to inform the optimization of the microfluidic device design to improve 
intracellular delivery and throughput. We show convection to be a powerful driving 
mechanism for intracellular delivery of large macromolecules (>2 MDa), especially in 
comparison to diffusion alone. We also determine that cell VECT has minimal impact on 
nuclear envelop integrity, protein loss, and long term cell viability and proliferation. Cell 
VECT enables new applications for microfluidic molecular delivery, including high-
throughput delivery of large macromolecules and particles for cell labeling, analysis, 
transfection, and gene editing. This work has elucidated a new cell phenomenon with great 
potential to serve as a nearly universal intracellular delivery platform for a variety of 
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A.1    Protocols 
A.1.1    Cell VECT Device Fabrication Protocol 
Overview of Steps: 
1. PDMS molding 
2. Cleaning PDMS and glass slide 
3. Bonding PDMS to glass slide 
 
PDMS Molding 
1. Thoroughly mix polydimethylsiloxane (PDMS) with crosslinker in 10:1 
PDMS:crosslinker ratio.  
2. Check silicon wafer mold for cleanliness.  
a. Clean with air gun for dust. 
b. Clean with IPA and DI water for smudges. Thoroughly dry the mold before 
use.  
3. Place silicon wafer mold in baking dish, pour mixed PDMS and crosslinker on top. 
4. Degas the PDMS in vacuum desiccator until all bubbles are removed.  
5. Use enough PDMS such that the PDMS layer is at least ~5 mm thick over the 
surface of the wafer.  
6. Bake PDMS in oven at 80⁰C for 1 hr.  
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7. After cooling, carefully release the PDMS from the wafer. 
a. Cut/pull the PDMS away from the edges of the baking dish. 
b. Gently remove the PDMS and wafer from the baking dish by lifting the 
PDMS equally from all sides.  
i. Use careful, gradual motions, as this is a step at which the wafer is 
more likely to break.  
c. Remove PDMS film from the back of the wafer.  
d. Gradually lift PDMS around the edge of the wafer until wafer is fully 
released.  
i. Peel PDMS off the entire perimeter, then gradually release the 
PDMS from the wafer equally around the perimeter, working your 
way in. Again, use careful, gradual motions, as this is a step at which 
the wafer is more likely to break.  
 
Cleaning PDMS and Glass Slide 
1. Cut devices out of PDMS.  
a. Cut in straight rectangles.  
2. Punch holes at inlets and outlets using biopsy punches. 
a. Always keep PDMS pattern side up 
b. Place a soft surface underneath the PDMS to prevent dulling the biopsy 
punch. A spare slab of cured PDMS is suitable, or something similar.  
c. Hold biopsy punch from the back, push straight down, perpendicular to the 
PDMS surface, punch, pull straight out, do not twist.   
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d. Use 1 mm biopsy punch for inlets and outlets. This corresponds to a 18 
gauge needle.  
e. Observe that punches are clean and cylindrical. If punches are jagged, use 
a new punch. 
3. Cover the PDMS devices, both sides, with Scotch tape, apply even pressure with 
thumb to remove dust. Keep taped until ready to bond.   
a. Clean glass slides by taping with Scotch tape.  
4. Check the quality of the devices before bonding.  
a. Don’t touch pattern, keep pattern side up at all times.  
b. Move devices to Petri dish with pattern side up.  
c. Observe all devices under microscope at 5x magnification, make sure entire 
pattern is free of dust, channels and ridges are intact, properly formed, and 
undamaged, then tape off the pattern surface until ready to bond.   
 
Bonding PDMS to Glass Slide 
1. Turn on Harrick Plasma Cleaner and leave on until after bonding process is 
complete, leave pump and RF knob off until ready to bond. 
2. Put PDMS & glass slide face up on plasma bonder sample tray.  
3. Plasma cleaner door knob: ↓ = closed, → = open, ← = valve-controlled. 
4. Turn valve 45 degrees from closed, leave at that setting.  
5. Place plasma bonder sample tray with glass slide and PDMS into plasma bonder. 
a. Set knob to closed (↓ = closed). 
b. Vacuum out the plasma chamber for 1 minute. 
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6. Turn RF to high, turn knob to valve-controlled (← = valve-controlled). 
a. Plasma should form immediately. 
b. Plasma color should be bright pink/purple.  
c. Blue plasma indicates not enough oxygen. Ensure that the valve is 45 
degrees from closed to allow a small amount of oxygen into the channel.  
d. Dark purple plasma indicates insufficient vacuum. Ensure the valve is not 
too far open (more than 45 degrees from closed), or that the door is properly 
closed, and the doorknob is turned to valve-controlled (← = valve-
controlled).  
7. Immediately after 1 min plasma bonding:  
a. Turn RF off.  
b. Turn pump off.  
c. SLOWLY rotate knob to open (→ = open). Repressurizing the chamber too 
quickly can cause samples to move around. Wait until hissing air stops 
before opening the door and removing the sample tray.  
8. Immediately place PDMS, pattern side down, on glass slide, gently tap edges and 
sides of channel with tweezers to form fully bonded surface, no bubbles. 
a. Do not tap on top of the channels, can cause channels or ridges to bond to 
the glass slide. 
9. Label slides with your initials, device specs, and date, transfer to 60-80°C oven 
for 1-2 hours.  
10. Remove devices from oven and let cool to room temperature. A representative 
image of a properly bonded device is shown in Figure A. 1. 
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11. Observe all devices under microscope at 5x magnification, make sure entire 
pattern is free of dust and channels are properly bonded.  
12. Store devices in closed containers, away from dust and contaminants.  
 
 
Figure A. 1: Bonded PDMS device. Example image of a PDMS device made with the 
standard device fabrication protocol. The device is PDMS throughout, bonded to a glass 
slide. A correctly bonded device will have fine channel features that are clearly defined 










A.1.2    Cell VECT Glass-Reinforced Device Fabrication Protocol 
Overview of Steps: 
1. Apply thin PDMS layer to silicon mold 
2. Place glass slides on thin PDMS layer 
3. Pour and cure thick PDMS layer on top 
  
Apply Thin PDMS Layer: 
1. Thoroughly mix PDMS with crosslinker at 10:1 PDMS:crosslinker ratio. 
2. Degas 10:1 PDMS in a vacuum desiccator. 
8. Check silicon wafer mold for cleanliness.  
c. Clean with air gun for dust. 
d. Clean with IPA and DI water for smudges. Thoroughly dry the mold before 
use.  
3. For a 100 mm diameter wafer mold, apply 4 mL 10:1 PDMS to the surface for a 
PDMS layer ~ 0.5 mm thick, tilt to coat the entire wafer surface evenly. 
4. Cure the thin 10:1 PDMS layer in 80⁰C oven until fully cured (~5-10 mins). 
a. Check that the thin PDMS layer is cured by gently tapping the layer over 
an empty part of the wafer with a pipet tip.  
 
Place Glass Slides on Thin PDMS Layer: 
1. Use a glass cutter to cut standard, 1 mm thick microscope slides. 
a. Fit the slide dimensions to fully cover the microfluidic channel, but not the 
inlets and outlets, approximately 4 mm by 10 mm.  
 149 
b. Clean the cut glass with Scotch tape to remove glass fragments.  
2. Coat one side of each glass slide with a very thin layer of uncured 10:1 PDMS. 
3. Carefully place the glass slide PDMS-side down onto the cured thin PDMS layer 
on the wafer. 
a. Gently press on the slide to remove air bubbles. 
b. Make sure the glass slide does not cover the inlet or outlet regions. 
4. Bake in 80⁰C oven until the glass slides are cured into place (~5-10 mins). 
a. Ensure the glass slides are cured into place by gently pushing the glass 
slides with a pipet tip.  
b. This prevents the glass slides from drifting out of place when the thick 
PDMS layer is poured on top.  
 
Pour and Cure Thick PDMS Layer: 
1. Pour 40 mL of premixed and degassed 10:1 PDMS on top of the cured thin 
PDMS layer and glass slides. 
a. Wafer should be in a container that is approximately the same size and 
shape as the wafer. 
b. Use a sufficient amount of 10:1 PDMS for this thick PDMS layer such 
that the overall PDMS layer is at least ~5 mm thick over the surface of the 
wafer. 
c. Fully degas the PDMS in a vacuum desiccator if necessary. 
2. Cure in 80⁰C oven for 1 hour. 
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3. Allow to cool before gently releasing the PDMS from the wafer. 
a. Release the PDMS very slowly, taking extra care not to rip the thin PDMS 
layer off of the embedded glass slides. 
4. Once released, tape the PDMS device features to prevent dust contamination.  
5. Proceed to standard cleaning and bonding procedures described in Section A.1.1. 
6. A complete glass-reinforced device should look like Figure A. 2.  
 
 
Figure A. 2: Glass-reinforced PDMS device. Example image of a PDMS device with 
glass reinforcement. A small glass slide has been cut to fit the device layout, so that it 
covers the channel and ridges without impinging on the inlet and outlet regions. The small 
glass slide is embedded inside the PDMS, just above the channel features. The device has 







A.1.3    General Cell VECT Device Operation Protocol 
Experiment Preparation (Complete before experiment)  
1. Cell flow buffer recipe: 
a. 30 mL PBS (-/-) + 40 mg BSA + 1.6 mg EDTA (11 uL of 0.5M stock) + 10 
mL Percoll. 
b. Filter the buffer with sterile filter (0.2 μm), store in fridge. 
c. Flow buffer is optional, can use PBS, media, Opti-MEM, etc.  
2. Passivate devices and syringe/needle with 1% BSA in DI water (sterile filtered). 
a. Flush dust out of all needles and tubing using EtOH and DI water.  
b. To plug needles into the microfluidic chip, carefully align the needle with 
the opening and guide it into the punches using gentle pressure. Do not force 
the needle, as this can damage the PDMS punch.  
c. Flow 1% BSA through device using syringe, leave extra BSA in needle. 
d. If passivating devices overnight, store the devices in the fridge and cover 
the inlets and outlets with tape 
e. If using the devices the same day, passivate at room temperature for 
>20mins. Tape is not necessary, but leave a large droplet of 1% BSA at the 
outlets to prevent the channel from drying out.  
f. Prep at least twice as many devices as you will need in case of device 







g. Set syringe diameter on pump (Harvard apparatus syringe selection guide).  
h. Program the syringe pump to the desired flow rate.  
i. Experiments that require tubing can sometimes result in cell loss due to cells 
settling at low points in the tubing. To prevent this, position the syringe 
pump above the device, and position the tubing so that it follows a 
consistent downward path toward the device, as pictured in Figure A. 3.  
 
Figure A. 3: Syringe pump setup relative to microfluidic device. To prevent cell settling 
at low points in the tubing, elevate the syringe pump above the device. Position the tubing 
so that the path that the cells take from the syringe to the device is consistently downhill, 
so that there are no local low points at which cells can settle.  
2. Microscope 
a. Place device on microscope stage to observe cell flow if desired. 
b. Make sure light is off throughout collection of photo-sensitive samples. 
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3. Prime the tubing and needles by flowing through 1% BSA or buffer until a liquid 
droplet forms at the tip of the needle, tapping to remove all bubbles.  
4. Leave a large drop of 1% BSA at inlet so needle will have a liquid-liquid interface. 
5. If necessary, flow additional 1% BSA or buffer through device immediately 
before use to remove all bubbles. 
6. Prep buffer: 
a. Add 0.3 mg/mL FITC-dextran or other desired amounts or types of reagents 
directly to cell flow buffer. 
7. Prep cells: 
a. Complete all other prep first to minimize time cells are out of culture. 
b. Thoroughly resuspend cells in cell flow buffer with molecules by pipetting 
repeatedly.   
c. Pass cell suspension through cell strainer (>2X larger than cell diameter)  
d. Dilute cells to proper concentration (~1-10 x 106 cells/mL buffer) 
e. To prevent cell viability loss during longer experiments (≥ 1 hour), store 
cells on ice until ready to use.  
 
Experiment Run 
1. Load cells into the syringe.  
a. Eject any remaining 1% BSA from syringe, tubing, and needle. 
b. Uptake cells into syringe and tap to remove all bubbles from syringe, tubing, 
and needle. 
c. For photosensitive experiments, cover the syringe and tubing with foil. 
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d. Load the syringe into the syringe pump. 
e. To prevent cell viability loss during longer experiments (≥ 1 hour), tape a 
small cold pack onto the syringe.  
2. Ensure needle is fully primed with cell solution, then attach to cell syringe inlet. 
3. Keep samples on ice until experiment is complete.   
4. If using a microscope, observe that cells are flowing through the microchannel 
without major clogs or bubbles. 
a. For photosensitive experiments, turn off microscopy light during sample 
collection.  
5. When experiment is fully operational, collect fluid from outlets using pipets.  
a. Can save effort by plugging pipet tips into outlets, as shown in Figure A. 4. 
 
Figure A. 4: Microfluidic device setup on microscope stage. Typical setup image of a 
single-inlet, single-outlet microfluidic device on a microscope stage. The needle is attached 
to tubing and is plugged into the inlet. A pipet tip is plugged into the outlet to collect the 
sample (orange fluid).  
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A.1.4    Cell VECT Sterile Transfection Protocol 
1. Autoclave microfluidic devices, needles, and syringes in sterilization pouches. 
a. Allow to fully cool before use. 
2. If working with nucleic acids that are sensitive to degradation, clean the BSC work 
surface with RNase AWAY decontamination reagent.   
3. Use sterile syringe and needle to passivate devices with sterile 1% BSA in DI water. 
a. Make sure syringe, needle, and device are free of bubbles. 
b. Passivate at RT for >20 mins in BSC. 
c. Flush devices with sterile PBS (-/-) after passivation, leaving a large droplet at 
the inlet to prevent the channel from drying out.  
4. Plug sterile pipet tip into device outlet for sample collection.  
5. Spin down cells and wash once with PBS (-/-). 
6. Resuspend cells at 1-10x106 cells/mL in serum-free media (Opti-MEM).  
7. (Optional) pass cell suspension through a sterile cell strainer (>2X larger than cells) 
to remove aggregates. 
8. Add transfection payload at desired concentration to cell-media suspension. 
9. Load cells into sterile syringe with needle.  
10. Prime the needle by gently pushing the syringe plunger until a very small droplet of 
cell suspension forms at the tip of the needle.  
11. Plug the primed needle into the device inlet.  
a. Guide the needle into the inlet punch using gentle pressure. Forcing the needle 
could damage the PDMS inlet punch, 
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b. The primed needle should form a liquid-liquid interface with the droplet at the 
inlet, which prevents air from entering the channel.  
12. Flow cells through device using a syringe pump. 
a. Syringe pump should be cleaned with ethanol, then placed in the BSC. 
b. To minimize reagent waste and void volume in the setup, attach the needle 
directly to the syringe and plug the needle directly into the device inlet, as 
shown in Figure A. 5.  
c. Cells will collect at the sterile pipette tip. A barrier pipette tip can be used for 
sample collection to minimize contamination.  
 
Figure A. 5: Sterile microfluidic device setup in BSC. Example setup for sterile 
microfluidic device operation in a biosafety cabinet. This setup utilizes a needle attached 
directly to the syringe without tubing to minimize void volume and reagent waste. The 
device is elevated so that the needle can plug directly into the inlet without tubing. A barrier 
pipette tip is plugged into the outlet to collect the cell sample and minimize contamination 
risk.  
13. Rest cells, undiluted, for 10 minutes after processing. 
14. Gently plate cells in pre-warmed culture media at desired culture density.  
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A.2    Evolution of Device Design 
 Over the course of this thesis work, the cell VECT microfluidic device design has 
undergone several rounds of revisions that were informed by experimental findings. These 
changes were made to improve intracellular delivery efficacy, simplify device use and 
setup, and increase cell throughput. Numerous design changes have been made to various 
aspects of the device design, including the number of inlets, outlets, and channels, and the 
geometry of the channels and ridges. The device design initially used for cell VECT 
experiments had originally been developed for cell sorting based on mechanical properties 
[1-3]. This design had three inlets: one cell inlet flanked by two sheath inlets to focus the 
cell flow down the center of the microfluidic channel. The design had a single microfluidic 
channel and multiple outlets to facilitate fractionation of the inlet cell population into 
multiple outlet subpopulations (Figure A. 6A). The ridges had a diagonal orientation for 
directed cell deflection along the slant based on mechanical properties [1-3].  
As a result of several device iterations, various device design changes have been 
made. To simplify device use and setup, the device design was modified to utilize only one 
inlet and one outlet. Removing the sheath inlets simplified device setup and reduced 
reagent waste, since the sheaths inlets needed to contain the same concentration of target 
molecules as the cell inlet. The sheath focusing was replaced by serpentine inlet channels 
designed to focus cell flow to the center of the ridged microchannel [4,5]. The ridges were 
modified from a diagonal geometry to chevrons that focus cells to the center of the ridge 
field to further facilitate cell processing through the ridges without sheath focusing. These 
changes helped to improve delivery efficiency. To increase cell throughput on a single 
microfluidic chip, a manifold with multiplexed channels was added, such that several 
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microfluidic processing channels could operate from a single cell inlet. This multiplexed 
processing was facilitated by the removal of the multiple cell outlets. The overall product 
of these design changes can be visualized in Figure A. 6B. These design changes have 
increased the throughput of a single microfluidic chip from ~104 cells/min in the original 
design to up to and exceeding 107 cells/min in the new manifold devices. The throughput 
of a single chip can easily be increased further by multiplexing the device microchannels 
in 2 dimensions, with an increased number of microchannels side-by-side, or in 3 
dimensions by stacking multichannel devices on top of each other or creating 3-
dimensional multiplexed processing channels through injection molding. The 
simplification of the microfluidic setup due to the removal of unnecessary inlets and outlets 
is shown in Figure A. 6C,D.  
 
Figure A. 6: Evolution of a device. (A) Initial experiments were carried out on a 
microfluidic device originally designed for cell sorting. This design used multiple inlets 
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for sheath focusing and multiple outlets for cell fractionation. The device has a single 
processing channel with diagonal ridges. (B) An evolved device design exhibiting the 
results of several design revisions. The sheath focusing inlets were replaced with serpentine 
focusing channels and chevron focusing ridges. The multiple outlets were consolidated into 
a single outlet. The single inlet and outlet facilitates multiplexing of the channels for higher 
throughput. (C) Operation of the original design requries additional setup due to the 
multiple inlets and outlets. (D) The removal of unnecessary additional inlets and outlets 
simplifies the setup and operation of the new device design.  
Many of the design changes were informed by experimental results that elucidated 
the mechanism and governing parameters of cell VECT delivery. Since faster cell 
compression was shown to increase cell volume loss and improve intracellular delivery, 
we increased the flow rates at which the devices are operated [7]. At high flow rates, the 
flexible PDMS microchannel can deform due to internal fluid pressure, which can change 
the channel height. We analyzed PDMS microchannel deformation using extra-fine 
microscope objective focusing on the beginning of the ridge field, where deformation 
would be highest [8,9]. Our microfluidic cell volume change experiments were conducted 
at flow rates in which deformation of the PDMS microchannel and ridges was not 
detectable (<1 μm). In order to maximize intracellular delivery through rapid compression, 
we utilize the devices at higher flow rates with the addition of glass slide reinforcement, 
which has been shown to significantly minimize pressure-induced PDMS microchannel 
deformation (Figure A. 7) [10,11]. At the highest operating flow rates in our glass-
reinforced devices (800 μL/min) deformation of the PDMS microchannel and ridges was 
not detectable (<1 μm).  
Since results showed that repeated compressions resulted in greater intracellular 
delivery, the number of ridges on subsequent device designs was increased to >22 to 
maximize delivery (Figure A. 7) [6]. We also increased the spacing between ridges to 
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facilitate cell relaxation between compressions, which was shown to increase delivery 
(Figure A. 7) [6]. Smaller compression ridge gaps were used to increase volume loss and 
improve delivery (Figure A. 7) [6]. The faster flow rates also enabled the devices to operate 
with a smaller compression ridge gap, ≤50% of cell diameter, without cells flowing around 
the ridges or clogging the ridges. However, we refrained from using ridge gap sizes <20% 
of cell diameter; we observed that cells that are rapidly forced through a compression ridge 
gap that is too small (<20% of cell diameter) had lowered viability. Some cells also undergo 
lysis at these extreme compression conditions, which can cause clogging of the ridges due 
to cell debris. The clogged channel lowers cell throughput, processing efficiency, and cell 
recovery. Therefore, to avoid these adverse impacts on cell processing, we used 
compression ridge gaps >25% of cell diameter. We also filter out potential clogging agents, 
such as dust and nonviable cell aggregates, using a cell strainer with pore diameter that is 
~2X the size or greater than that of the average cell diameter. Overall, our device design 
and protocol changes were informed by experimental studies into the governing parameters 
of cell VECT in order to maximize delivery efficiency and throughput.  
 
Figure A. 7: Schematic of device design features to improve intracellular delivery. 
The compression ridge gap height (Hg) is decreased to ≤50% of cell diameter. The distance 
between ridges (Lr) is increased to facilitate cell recovery between ridges. The number of 
ridges (N) is increased to > 22 to improve delivery. The presence of a glass slide (G) is 
added to facilitate higher flow rate, and therefore faster compression, without PDMS 
channel deformation.  
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Multiple design changes were developed in conjunction with the single-inlet device 
design in order to facilitate high cell processing efficiency. The single-inlet devices no 
longer have the sheath focusing flows from the sheath inlets, and therefore cell flow is not 
focused through the ridged microchannel (Figure A. 8A). Therefore, we introduced 
additional design features, serpentine focusing and smaller ridge gutters, to compensate for 
the lack of sheath focusing (Figure A. 8B). In the unfocused devices, we observed ~20% 
of cells flowing in the gutter region of the device (Figure A. 8C). The gutter region, the 
space at the outer edges of the microchannel past the ends of the ridges (shown in red in 
Figure A. 8C,D), is intended only to provide an escape mechanism for dead cells and cell 
aggregates that would normally clog the device, but in the unfocused devices result in a 
significant portion of viable cells flowing around the ridges without being processed. To 
mitigate this effect, we reduced the size of the gutters by half or more, and introduced a 
serpentine channel following the inlet that focuses the cell flow through the center of the 
microchannel [4,5]. These design features reduced the percent of cells in the ridge gutter 
by over half (Figure A. 8D). An overview of device design changes and the reasoning 
behind them is described in Table A. 1. 
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Figure A. 8: Device design features to minimize gutter cells. (A) Removal of the sheath 
inlets resulted in an unfocused, single-inlet device design. (B) Introducing a serpentine 
channel after the inlet allows for cell flow focusing in a single-inlet device. (C) In the 
unfocused device design, approximately 20% of cells go unprocessed by flowing around 
the ridges in the gutter region (red) of the microchannel. (D) In the serpentine focusing 
device with 50% smaller gutters, the percent of cells in the gutter region (red) is reduced 
by over half.  
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